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Abstract
Haem oxygenase-1 (HO-1) is the inducible form of the enzyme responsible for 
the breakdown of haem, metabolising it to carbon monoxide (CO), bilirubin and 
iron. Protective properties have been attributed to HO-1 induction and haem 
breakdown products. Upregulation of HO -1 has been reported in many 
neurodegenerative disorders and it has been postulated that this may play an 
important role in the stress defences of the cell. Inducible nitric oxide (iNOS) 
activity, nitric oxide production and mitochondrial dysfunction are also reported 
in neurodegenerative disorders and it has been shown that inducers of iNOS also 
induce HO-1. Rat astrocytes have been used to examine possible interactions 
between the iNOS/HO systems by inducing iNOS activity with IFNy/LPS and 
HO-1 with hemin. It was confirmed that IFNy/LPS mediated NO production 
caused an upregulated HO-1 expression and an increase in HO activity. Further, 
it was shown that hemin treatment was able to prevent the previously reported 
NO mediated irreversible inhibiton of complex IV of the mitochondrial electron 
transport chain seen when astrocytes are treated with IFNy/LPS. Hemin plus 
IFNy/LPS treatment was accompanied by an increase in HO activity and an 
increase in glutathione (GSH) levels and it is postulated that together these 
confer protection.
It may be concluded from this thesis that there are complex interactions between 
HO and NOS which could contribute to the ability of astrocytes to provide 
protection to neurones against oxidative and nitrosative stress. This may be 
relevant to mechanisms by which neurodegeneration occur.
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Chapter 1.
Introduction
15
In recent years, study of Haem oxygenase (HO) (EC 1.14.99.3) the enzyme that 
metabolises haem to carbon monoxide (CO), iron and biliverdin, has led to the 
suggestion that the inducible form is important in the antioxidant defences of the 
cell. The mechanisms of protection are not fully understood, indeed it appears in 
some cases that induction of HO can actually prove harmful. Expression of 
inducible HO is documented in many disease states including those that cause 
neurodegeneration (Schipper, 2004).
This thesis has investigated the effects of induction of HO in rat astrocytes and 
its interaction with inducible nitric oxide synthase (iNOS)/nitric oxide (NO). 
This chapter will introduce haem and the HO family of enzymes, examine the 
pro and antioxidant effects that induction of HO can cause, then go on to discuss 
oxidative stress and the roles of HO and NO in neurodegeneration. Interactions 
between the iNOS/HO-1 enzyme systems will be examined and their relevance 
to neurodegeneration discussed. Finally the aims of the thesis will be explained.
1.1 Haem
Haem (Figure 1.1.), also known as iron protoporphyrin IX, is a member of the 
porphyrin family of compounds. Porphyrins are cyclic tetrapyrroles in which the 
four pyrrole rings are attatched through four methylene bridges. Porphyrin 
molecules alone do not bind O2 nor participate in enzyme catalysed reactions, 
these properties are conferred on the porphyrin molecule by the chelation of 
multi-valent transition metals such as iron, tin or zinc and attachment of the
16
c h 2
I
CHCH
CHHC
N
CHH C =
Figure 1.1. The structure of haem
M = methyl group, P = propionyl group, 
(adapted from Scheffler, 1999)
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protein moiety (Chang et al., 2005). When iron is chelated by the porphyrin 
haem is the resulting molecule. When ferric protoporphyrin IX binds a hydroxyl 
ion it is called hematin; if it binds a halide or acid anion it is hemin (Maines, 
1984). The site of haem synthesis is split between the cytoplasm and the 
mitochondria. Synthesis starts and finishes in the mitochondria with all 
intermediate steps taking place in the cytoplasm (Figure 1.2.). The capacity of 
the chelated Fe ion to undergo a reversible change in the oxidation state (Fe2+ <-»• 
Fe3+) makes haem compounds effective biological catalysts. Haem promotes 
most biological oxidation processes and is therefore important in cellular 
homeostasis. Haem serves as a prosthetic group for proteins involved in oxygen 
transport, mitochondrial respiration, drug metabolism, steroid biosynthesis, 
cellular antioxidant defenses, and signal transduction (Maines, 1997)
Free haem does not accumulate normally in tissue, this occurs only under 
pathological conditions (Maines, 1988). The term ‘free haem’ refers to the 
molecule before it is incorporated into haemoproteins, or when these proteins are 
being broken down.. Free haem is quite hydrophobic, readily enters cell 
membranes, and can greatly increase cellular susceptibility to oxidant-mediated 
killing (Jeney et al., 2002). Indeed it has been shown that free haemoglobin in 
plasma when oxidised can provide haem to endothelium which can enhance 
cellular oxidant mediated injury (Jeney et al., 2002). Free haem is always 
available, due to the constant breakdown of haemoglobin containing haem from 
erythrocytes and other enzymes using haem as a prosthetic group. Transporting 
heme via the circulatory system would expose the system to excessive toxicity 
via free radical production and oxidative stress and this may be the reason why
18
haemSuccinyl Co A 
+ glycine
Protopoiphyrin IX
Delta-aminolevulinic 
acid / Protoporphyrinogen
cytoplasm
porphobilinogen Uroporphyrinogen III
Uroporphyrinogen I
Coproporphyrinogen
III
Coproporphyrinogen
I
Figure 1.2. Haem synthesis pathway
Enzymes are, 1. delta-aminolevulinic acid synthetase, 2. delta-aminolevulnic acid 
dehydratase, 3. uroporphyrinogen I synthase and urophyrinogen III cosynthase, 
4. uroporphyrinogen decarboxylase, 5. coproporphyrin III oxidase, 6. 
protoporphyrinogen IX oxidase, 7. ferrochetalase.
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there is a requirement for haem degradation rather than a mechanism of haem 
reutilization (Sassa, 2004).
1.2. The haem oxygenase family of enzymes
In 1964 the enzymatic degradation of haem to bilirubin was first demonstrated in 
vitro by Wise & Drabkin, (1965). This finding was confirmed by Tenhunen et 
al., (1968) who went on to characterise the enzyme and its cellular location. 
Interest in haem oxygenase as the enzyme was named, was rekindled in the 
1980s when an inducible form, named HO-1 was discovered (Keyse & Tyrell, 
1989) which was identical to heat shock protein 32 (hsp 32) and caused interest 
in HO as a stress protein. It was noted that HO-1 appeared to be induced by 
various forms of oxidative stress and it was proposed that induction of the 
enzyme provided cellular protection against these insults (Stocker, 1990). To add 
further weight to this theory, both haem and HO are highly conserved molecules 
across almost all forms of life (Morse & Choi, 2002) and molecules so 
evolutionarily conserved and ubiquitous usually serve a fundamental purpose. 
The HO reaction involves the oxidation of haem to biliverdin, carbon monoxide 
(CO) and free iron. Biliverdin is subsequently reduced to bilirubin by the action 
of biliverdin reductase (EC 1.3.1.24).The reaction requires O2 and reduction of 
haem iron from Fe3+ to Fe2+ Nicotinamide adenine dinucleotide phosphate 
(NADPH) is the source of the reducing equivalent (Maines, 1997). (Figure 1.3). 
To date there have been 3 isoforms of HO described. The isozymes are different 
gene products and also differ in
20
Haem
Haem
oxygenase
r
Biliverdin
Biliverdin
reductase
NADPH +30-
Bilirubin
NADPH
NADP
2NADP+
+ 3H20
Figure 1.3. The haem oxygenase reaction
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nucleotide sequences, amino acid composition, transcript number and size (Cruse 
& Maines, 1988).
1.2.1. Haem oxygenase -  1
HO-1 is the HO isozyme which will be studied in this thesis. As mentioned 
previously HO-1 was identified as hsp-32 in 1989, and since that time it has 
become clear that it is responsive to many types of stimuli, including all those 
stimuli capable of causing oxidative stress (Maines, 1997). In normal unstressed 
conditions the spleen is the only organ in the body where HO-1 is the 
predominant isoform expressed, due to the constant breakdown of senesent 
erythrocytes (Braggins et al., 1986). The protein has 288 amino acids and a 
molecular mass of between 30,000 and 33,000Da (Shibahara et al., 1985). 
Expression is thought to be mainly regulated at the transcriptonal level 
(Rizzardini et al., 1993; Choi & Alam, 1996; Durante et al., 1997; Fogg et al., 
1999). Differences do exist though between species in HO-1 regulation, for 
example the rat HO-1 promoter has a heat shock responsive element which is not 
functional in the human gene (Okinaga et al., 1996). However for rat, mouse and 
human, the extent of homology for HO-1 is greater than 80%. Neither human or 
rat HO-1 contain any cysteine residues (Shibahara, 2003). Poss & Tonegawa 
(1997) report that HO-1' ' mice were unable to produce viable litters and showed 
partial prenatal lethality when crossed with heterozygotes. Surviving mice 
develop progressive inflammatory disease characterised by splenomegaly, 
lymphadenopathy, leukocytosis, and hepatic and renal inflammation. In addition 
the animals display increased iron accumulation and are more sensitive to 
oxidative stress. One case of human HO-1 deficiency has been reported (Yachie
22
et al., 1999) with similar clinical features to the HO-1 knockouts, however in the 
case of human HO-1 deficiency it appears that there is even more sensitivity to 
oxidative stress and the patient in this case died at age 6 (Kawashima et al.,
2002). It is worth noting that the mother of the child in this case had experienced 
two intrauterine deaths making it likely that mutations of the haem oxygenase 
gene are generally lethal in utero (Kawashima et al., 2002).
1.2.2. Haem oxygenase -  2 & 3
HO-2 is a constitutive isozyme and is the major HO isoform found in all organs 
(except as mentioned in spleen). Unlike HO-1 it is only responsive to adrenal 
glucocorticoids (Maines, 1997). Human HO-2 has 316 amino acid residues and a 
molecular mass of 36000Da and contains 3 cysteine residues (Shibahara, 2003). 
Unlike HO-1, HO-2 contains 2 copies of the haem binding site, a dipeptide of 
cysteine and proline (CP motif) which are not involved in haem breakdown. 
These CP motifs are conserved at equivalent positions in human, rat and mouse 
HO-2 (Shibahara, 2003). This indicates that HO-2 may function as a ‘haem 
regulator’, binding haem to maintain the intracellular haem level or to prevent 
haem from causing oxidative stress. Erythroid type 5-aminolevulnic acid 
synthase also contains the CP motifs (Lathrop & Timko, 1993), suggesting a 
possibility that haem itself may regulate its degradation and synthesis. HO-2 
knockout mice show a milder phenotype than HO-1 knockouts with no 
noticeable morphological alterations. HO-2 deficient mice are fertile (Poss et 
al., 1995) but HO activity is markedly reduced in the brain and males show 
ejaculatory abnormalities and reduced mating behaviour (Burnett et al, 1998) and
23
they show increased susceptibility to hyperoxic lung damage (Dennery et al., 
1998).
McCoubrey et al, (1997) reported the existence of a third isoform, HO-3 in the 
rat in 1997, in organs including the spleen, liver, kidney and brain. They reported 
a tissue distribution similar to that of HO-2 . The predicted amino acid structure 
of HO-3 was different to HO-1 and HO-2 but with a 90% sequence homology to 
HO-2 and only marginal HO activity (0.4 nmol bilirubin/min/mg protein 
compared to specific activities of 107 and 67 nmol bilirubin/min/mg protein for 
purified rat hepatic HO-1 and testicular HO-2 (Trakshel et al., 1986), 
respectively). A recent report (Hayashi et al., 2004) has suggested that HO-3 is 
not in fact expressed in rat tissues and that there are no functional HO-3 genes in 
rat. Hayashi et a l, (2004) set out to examine the structure of the rat HO-3 gene 
and detect any possible HO-3 transcripts and products in rat, and although they 
did discover two HO-3 genes, they concluded that they are in fact pseudogenes, 
which are not functional.
1.3. The products of haem breakdown
The haem oxygenase reaction as mentioned previously metabolises haem to CO, 
iron and biliverdin which is rapidly reduced to bilirubin by biliverdin reductase.
1.3.1 Carbon Monoxide
Historically this molecule has been thought of as a toxin and first came to the 
attention of biologists in 1857 when Claude Bernard described the affinity of CO 
for haemoglobin (Bernard, 1857, cited in Otterbein & Choi, 2000). This
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prompted research that placed CO in the category of poisons and toxins. Toxic 
effects of CO are caused by its ability to interact with iron, which is co-ordinated 
at the centre of all haem proteins (Piantadosi, 2002). CO can then inhibit the 
proteins ability to bind O2 (e.g. haemoglobin) or inhibit oxidation-reduction 
reactions requiring the transfer of electrons through the haem moiety (e.g. 
cytochromes) (Piantadosi, 2002). CO can also bind to proteins that contain other 
transition metals at the active site e.g., copper and can interfere with their 
functions (Piantadosi, 2002).
In 1963 the physiologist Ronald Cobum demonstrated that CO is produced by 
the bodies of humans and other animals (Coburn et al., 1963) and during recent 
years , research has shown that although CO at high concentrations is certainly 
lethal, low concentrations of this molecule can exert very different effects on 
physiological and cellular functions. For example, endogenous production of CO 
has been measured in cultured olfactory receptor neurons at ~ 4.7 pmol/mg 
protein (Ingi & Ronnett, 1995) and concentrations of between 50 and 500ppm 
CO have been shown to be cytoprotective against hyperoxia in rodents (Otterbein 
et al., 1999). Investigations have shown that low concentrations of CO can exert 
numerous biological functions such as neurotransmission (Maines, 1993; Snyder 
et al., 1998), protection against cell death (Brouard et al., 2000) anti­
inflammation (Otterbein et al., 2000), protection against oxidative injury 
(Otterbein et al., 1999), inhibition of cell proliferation (Morita et al., 1997; Song 
et al., 2002) and tolerance of organ transplantation (Sato et al., 2001; Song et al., 
2003). Biological functions akin to that of nitric oxide (NO) have been ascribed 
to endogenously produced CO in that it is able to bind to soluble guanylate
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cyclase thereby effecting the activation of cyclic 3’: 5’-guanosine
monophosphate (-cGMP). It could be argued, that because the capacity of NO to 
activate guanylate cyclase is 30-fold more effective than CO (Stone & Marietta., 
1994), it is not important in this area. However CO is a very stable molecule and 
can accumulate in the cell because it reacts exclusively with haem (Otterbein & 
Choi, 2000). The capacity of cells in the brain to generate CO is much greater 
than that to generate NO (Maines, 1997). Furthermore the simultaneous presence 
of NO and CO favourably affects binding of CO to haem (Maines, 1997). CO 
also exerts its effects via other pathways such as the mitogen activated protein 
kinase (MAPK) pathway, which involves phosphorylation cascades responsible 
for transducing inflammatory signals from the cell surface through to the 
nucleus, which could result in cellular activation and production of pro- 
inflammatory cytokines which amplify inflammation. CO has been shown to 
downregulate production of some pro-inflammatory cytokines such as TNF-a, 
IL-ip and IL-6, and at the same time upregulate production of the anti­
inflammatory cytokine IL-10 via the p38 and JNK MAPK pathways (Otterbein et 
al., 2000; Morse et al., 2003). It has also been shown that the anti-apoptotic 
action of CO is mediated via the p38 MAPK system (Brouard et al., 2000).
1.3.2 Bilirubin and biliverdin
Bilirubin is known as a potentially toxic agent, which may accumulate in the 
serum of neonates causing jaundice (Otterbein & Choi, 2000). In high 
concentrations it can deposit in selected brain regions and cause neurotoxicity 
(Gourley, 1997). However bilirubin is also the most abundant endogenous 
antioxidant in mammalian tissues and accounts for the majority of the
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antioxidant activity of human serum (Gopinathan et al., 1994). It has been 
reported that under low oxygen concentrations (2%) and when incorporated into 
liposomes, it scavenges peroxy radicals as efficiently as a-tocopherol (Stocker et 
al., 1987). Numerous studies have attributed protective effects to bilirubin. 
(Gopinathan et al., 1994; Kato et al., 2003; Sedlak & Snyder 2004). Higher 
baseline serum bilirubin levels have been reported to correlate with a lower 
incidence of myocardial infarction in men, maybe due to the inhibitory effect of 
bilirubin on the oxidation of low-density lipoproteins (LDLs) (Djousse et al.,
2003). In the laboratory, Dore et al., (1999) report protection of neurons against 
oxidative stress and Clark et al., (2000) report cytoprotection of smooth muscle 
cells by HO-1 derived bilirubin. Yamaguchi et al., (1996) report that bilirubin 
acts as a scavenger via its own oxidation to scavenge reactive oxygen species 
(ROS) produced by ischemia-reperfusion in the liver. Each molecule of bilirubin 
that acts as an antioxidant is itself oxidised to biliverdin which is immediately 
reduced back to bilirubin by biliverdin reductase (Figure 1,4.). Cell lines which 
are designed to express less biliverdin reductase have been reported to exhibit 
increased vulnerability to oxidative stress (Baranano et al., 2002). In addition, 
Biliverdin has been found to have anti-viral activity (Morse & Choi, 2005) and 
has also been shown to provide protection in a rat model of ischaemic injury 
(Vachharajani et al., 2000).
1.3.3 Iron
Free iron is released into the endoplasmic reticulum by haem breakdown. Iron is 
known to take part in Fenton chemistry, and generate the highly damaging 
hydroxyl radical (• HO) by acting as a catalyst for the Haber-Weiss reaction:
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H2O2 + O2' ------- ► 0 2 + 'OH + ’O H (l.l)
This reaction as written is exceedingly slow, with a reaction rate of 3.0 M ' 1 s’1 at 
neutral pH (Haber & Weiss, 1934). However iron causes the reaction to occur 
much more quickly:
Fe2+ + H20 2 ------- ► Fe3+ + OH + *OH (1.2)
Fe3+ + ascorbate ----- ► Fe2+ + ascorbate radical (1.3)
Fe3+ + 0 2'  * Fe2+ + 0 2 (1.4)
The rate constant for equation (1.2), which is known as the Fenton reaction, for 
EDTA chelated iron is 104M' 1 s' 1 at pH 7.0 (Sutton & Winterboume, 1984). The 
rate constant for equation (1.4) when the iron is chelated with EDTA has been 
determined to be 1 0 6M_1 s' 1 at pH 7.0. (Butler & Halliwell, 1982).
Thus free iron could and is known to have pro-oxidant effects on the cell. These 
effects include stimulation of membrane lipid peroxidation and causing 
sensitivity to other oxidants (Aust et al., 1985, Balia et al, 1990). However 
release of iron by the HO catalysed reaction results in the upregulation of ferritin, 
the iron storage protein (Eisenstein et al., 1991). This upregulation has proven to 
be cytoprotective in a model of oxidative stress (Balia et al, 1992) and Otterbein 
et al., (1997) have shown that when iron is chelated by the exogenous iron 
desferoxamine, no ferritin is induced and protection is ablated.
1.4. Pro and antioxidant effects of HO induction
Increased levels of HO-1 expression are seen in many disease states, not only 
those involving haem catabolism. For this reason many studies have been made 
on the induction and inhibition of HO expression and activity in many cells and
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Figure 1.4. The biliverdin-bilirubin cycle
Lipophilic reactive oxygen species act directly on bilirubin, leading to its 
oxidation to biliverdin. Biliverdin reductas catalyses the reconversion of 
biliverdin to bilirubin permitting bilirubin to detoxify a 10,000-fold excess of 
oxidants. (Adapted from Sedlack & Snyder, 2004).
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tissues both in vivo and in vitro. It has become apparent that the effects of HO 
activity and expression can be varied and not always entirely protective.
1.4.1. Protective effects of HO induction
Many of the studies that have found a protective role for HO expression/activity 
have attributed this protection to one of the products of haem breakdown, mainly 
bilirubin and CO. For example HO derived bilirubin has been found to be 
protective in a number of ways. In a rat model of cardiac ischaemia reperfusion 
injury bilirubin was shown to restore myocardial function and minimise both 
infarct size and mitochondrial damage (Clark et al., 2000). Micromolar 
concentrations of bilirubin used to rinse murine liver and cardiac grafts during 
ex-vivo organ reperfusion or preceeding in vivo transplantation attenuated biliary 
dysfunction and cell injury of rat livers (Kato et al., 2003). This protection 
mimicked the effect of HO-1 preconditioning of the livers. Exposure of aortic 
endothelial cells to a medium containing increased bilirubin levels which was 
derived from hemin treated cells markedly potentiated HO-1 expression and 
enzyme activity induced by NO donors (Foresti et al., 2003). This suggests that 
signalling actions of NO that are related to the induction of HO are affected by 
haem metabolites such as bilirubin and so increase protection (in this case) of 
vascular epithelium against nitrosative stress. CO has been shown to be 
responsible for arterial vasodilation through activation of guanyl cyclase (Morita 
et al., 1995; Morita & Kourembanas, 1995; Sammut et al., 1998). Haem which 
potently induces HO-1 has been shown to lower blood pressure in spontaneously 
hypertensive rats (Levere et al., 1990) and this is suggested to be mediated by 
CO. Expression of HO-1 has also been implicated in cellular protection by virtue
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of its expression alone . Taylor et al., (1998) found that induction of HO-1 in the 
rat lung protected against hyperoxia, but that this protection was still seen even 
when HO activity was inhibited. There is a possibility that ferritin which is co­
induced with HO-1 and acts to sequester iron is responsible for this protection, 
however it has been reported that HO-1 induction is not necessary for ferritin 
induction (Balia et al., 1995) so the mechanism for protection here is not entirely 
clear.
1.4.2. Possible Harmful effects of HO induction
The HO reaction can itself potentially generate hydrogen peroxide (H2O2), as a 
significant metabolic side product, as demonstrated by Noguchi et al., (1983).
Thus HO activity is a possible source of *OH because both H2O2 and Fe2+ are
released in the same microenvironment. In vitro studies have suggested that 
under certain conditions HO activity may potentiate, rather than attenuate 
oxidant toxicity. For example, Da Silva et al., (1996) found that inhibiting HO 
activity could actually attenuate toxic effects of an H2O2 challenge after a short 
term oxidative stress of epithelial cells, but a longer term incubation with hemin 
effectively protected against a later H2O2 challenge. Another study found that 
concurrently treating astroglial cells with inhibitors of HO activity such as Sn 
mesoporphyrin protected the cells against the cytotoxic effect of H2O2 treatment 
(Dwyer etal., 1998). Overexpression of HO-1 has also proved damaging in some 
cases. Suttner & Dennery, (1999) found that overexpressing HO in hamster 
fibroblasts proved cytoprotective only with low HO activity (less than five-fold 
compared to basal levels) however higher activity was correlated with significant
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oxygen cytotoxicity. It was concluded that this was due to increased levels of 
reactive iron.
1.5. Oxidative stress in the brain
Oxidative stress occurs when oxygen free radicals are generated in excess 
through the reduction of oxygen. Reactive oxygen species (ROS) consist of 
oxygen free radicals and associated entities that include superoxide (0 2 **) 
hydrogen peroxide (H2O2), singlet oxygen, nitric oxide (NO), and peroxynitrite 
(ONOO'). Some of these species are produced at low levels under normal 
physiological conditions and are effectively scavenged by a number of 
antioxidant molecules such as superoxide dismutase (SOD) glutathione, catalase 
and small molecules such as vitamins C and E (Chong et al., 2005) The 
superoxide radical is the most frequently occurring radical that produces H2O2 by 
dismutation. From this reaction it is then possible for the hydroxyl radical
(OH*)to be produced by the Haber-Weiss reaction (Equation 1.1) in the presence
of ferrous iron (Chong et al., 2005). It is also possible for the OH* radical to be
produced through an interaction of the superoxide radical and NO (Fubini & 
Hubbard, 2003). In this reaction NO reacts with superoxide which leads to the 
generation of peroxynitrous acid, and spontaneous decomposition of this acid 
forms the hydroxyl radical (Fubini & Hubbard, 2003). Indeed although NO is 
included as an oxygen free radical, it and other NO species have become the 
subject of numerous studies as reactive nitrogen species (RNS) due to their 
implication in the pathogenesis of many diseases.
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Oxidative stress occurs in the brain when the ability of the endogenous 
antioxidants is overridden by excess production of ROS/RNS. The brain is highly 
susceptible to oxidative stress for a number of reasons. Despite constituting 2% 
of body weight, the brain is known to possess the highest oxygen metabolic rate 
of any organ in the body (Maiese, 2002 in Ramachandran, 2002), and consumes 
about 20% of the total amount of oxygen in the body. This high metabolic rate 
leads to an increased likelihood of free radical generation over and above that 
with which endogenous defenses are able to deal. In addition to this brain tissues 
contain high amounts of unsaturated fatty acids which can be attacked by ROS 
(Chong et al., 2005), and high levels of iron which are associated with free 
radical injury (Herbert et al., 1994). Despite these “risk” factors for free radical 
generation and damage it is evident that antioxidant resources in the brain may 
be in fact lower than those found in other organs, for example catalase activity in 
the brain has been shown to be only 1 0 % of that found in liver (Floyd & Carney, 
1992).
The production of ROS/RNS can lead to cell injury and death through various 
mechanisms. Oxidative damage can cause cell membrane lipid destruction and 
cleavage of DNA (Vincent & Maiese, 2000; Wang et al., 2003), peroxidation of 
cellular membrane lipids (Siu & To, 2002), peroxidation of docosahexaenoic 
acid which is a precursor of neuroprotective docosanoids (Mukherjee et al., 
2004), the cleavage of DNA during the hydroxylation of guanine and 
methylation of cytosine (Lee et al., 2002), and the oxidation of proteins that yield 
protein carbonyl derivatives and nitrotyrosine (Adams et al., 2001). ROS/RNS 
can also have a detrimental effect on mitochondria and are able to inhibit 
respiratory chain complex enzymes in the electron transport chain (Figure 1.5.)
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Figure 1.5. The mitochondrial respiratory chain
The mitochondrial respiratory chain is an assembly of electron carriers grouped 
into four polypeptide complexes [I (NADH ubiquinone reductase), II (succinate 
ubiquinone reductase), III (ubiquinol cytochrome c reductase), and IV 
(cytochrome c oxidase). Complexes I, III, and IV act as oxidation-reduction- 
driven proton pumps and are associated with the coupling sites of 
phosphorylation. The flow of electrons from NADH or FADH2, along the 
respiratory chain to oxygen is coupled to the pumping of protons across the inner 
mitochondrial membrane, resulting in the formation of a proton gradient. The 
flow of protons back into the mitochondria through the membrane sector of the 
mitochondrial ATP synthatase alters the active site of the enzyme leading to the 
synthesis of ATP.
Q = ubiquinone, C = cytochrome c both act as mobile electron carriers.
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(Bolanos et al., 1994, Yamamoto et al., 2002) , resulting in energy failure and 
ultimately, cell death.
1.4.3. Mitochondria, the electron transport chain and sources of oxidative 
stress
Mitochondria are typically spherical or rod shaped double membrane bound 
organelles which are the major site of adenosine triphosphate (ATP) synthesis in 
the cell via oxidative phosphorylation. The inner membrane is the site of the 
mitochondrial electron transport chain (ETC), and where oxidative 
phosphorylation takes place (Mitchell, 1961). The ETC is comprised of more 
than 80 polypeptides which are grouped together into four enzyme complexes I - 
IV (Figure 1.5.) (Michel, 1998; Zhang et al., 1998; Sazanov et al., 2000). The 
ETC facilitates the transfer of electrons from NADH and FADH2 which are 
generated by carbohydrate and fatty acid metabolism, to oxygen which is then 
reduced to water at complex IV (cytochrome oxidase, EC 1.9.3.1) (Michel et al.,
1998). Electrons are passed along the chain through the redox centres of the 
respiratory complexes, via increasing reduction potentials. Mobile electron 
carriers act to pass electrons from complexes I (NADH ubiquinone reductase, EC 
1.6.5.3) and II (succinate ubiquinone reductase, EC 1.3.5.1) to complex III 
(Ubiquinol cytochrome c reductase, EC 1.10.2.2) (Ubiquinol) and from complex 
III to complex IV (cytochrome c) (Crofts et al., 1999; Tormo & Estomell, 2000). 
Electron transport through the complexes is coupled to the pumping of protons 
from the matrix into the inter-membrane space by complexes I, III, and IV 
(Mitchell, 1961; Videira, 1998; Michel, 1998; Crofts et al., 1999). This results in
35
an electrochemical gradient being formed across the membrane which is 
dissipated through the membrane domain of ATP synthase (EC 3 .6.3 .14) which 
leads to the phosphorylation of adenosine diphosphate (ADP) (Mitchell, 1961). 
The intramitochondrial compartment is highly reducing and various respiratory 
components including flavoproteins, iron- sulphur clusters and ubisemiquinone, 
are thermodynamically capable of transferring one electron to oxygen forming 
superoxide, (reviewed in Turrens, 2003). There are a number of mitochondrial 
sources of O2*' including several respiratory complexes and individual enzymes. 
Production of 0 2 *’ in mitochondria seems to vary from organ to organ and 
depends on whether mitochondria are actively respiring (state 3 respiration) or 
whether the respiratory chain is highly reduced (state 4 respiration) (Barja, 
1999). It has been reported that complex III seems to be responsible for the 
majority of the O2*’ produced in heart and lung mitochondria (Turrens and 
Boveris, 1980; Turrens et al., 1982) but that in the brain it is complex I that is 
mainly responsible for O2*’ production . Indeed in Parkinsons disease where 
oxidative stress is implicated as a causative factor complex I has been found to 
be the primary source of ROS (Betarbet et al., 2002; Nicholls , 2002). Formation 
of O2 " is also likely to increase if the ETC begins to become reduced (State 4 
respiration mentioned previously) by downstream “carriers” being inhibited 
causing electrons to “back-up” (Scheffler, 1999; Turrens, 2003).
1.6. HO and the brain
HO activity in the brain exceeds that of many systemic organs including the liver 
(Maines, 1997), This activity is mainly due to the action of the HO-2 isoform. 
Under normal unstressed conditions HO-2 is mainly expressed in neuronal
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populations (Ewing & Maines, 1992), and in the endothelial lining of blood 
vessels (Maines, 2000). HO-1 under normal unstressed conditions is only 
detectable in select neurons such as those in the dentate gyrus, cerebellum and 
brain stem (Sun et al., 1990; Ewing & Maines, 1991; Ewing & Maines, 1992; 
Vincent et al., 1994; Maines et al., 1998). However, in response to stress, HO-1 
is widely expressed in glial populations and macrophages (Ewing & Maines, 
1991; Ewing & Maines, 1992; Ewing et al., 1992; Geddes et al., 1996; Turner et 
al., 1998).
Because of the differences in distribution and regulation of HO-1 and HO-2 in 
brain, it has been suggested that HO-2 is responsible for normal functioning, 
maturation, aging and homeostasis of gaseous signal molecules (Maines, 2000). 
HO-1, therefore, could be important in cellular defence mechanisms, as it has a 
rapid response to stressful stimuli. Due to the relative deficiency of glutathione 
and ascorbic acid in neuronal tissue (Ewing & Maines, 1993) the antioxidant 
molecules that HO-1 activity produces may be of key importance here (Ewing & 
Maines, 1993).
1.7. HO-1 and neurodegeneration
As mentioned previously, upregulation of HO-1 is seen in many disease states, 
whether or not they are involved in haem catabolism. Neurodegenerative 
diseases are not exempt from this. The most common of these diseases and 
possible roles for HO-1 in the disease process will be described
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1.7.1. Aging
Although aging itself is a normal process and not a disease, neurodegeneration is 
a natural consequence of it. As previously mentioned HO-1 expression in normal 
brain is much less than that of HO-2 which under basal conditions is the main 
isoform of HO expressed in the brain. A study has recently shown that the 
numbers of neurons and neuroglia immunoreactive for HO-1 in the normal 
human cerebral cortex and hippocampus increase progressively between 3 and 84 
years of age (Hirose et al., 2003). It has also been shown that in normal elderly 
patients moderate HO-1 immunoreactivity was consistently observed in the 
cytoplasm of dopaminergic neurons of the substantia nigra pars compacta 
(Schipper et al., 1998) . This is in contrast to staining of other neurons in this 
area, which was faint or nonexistent. This has been suggested to be a response to 
oxidative stress due to the high levels of ROS generated in these cells by the 
enzymatic deamination and iron-mediated oxidation of dopamine (Stokes et al.,
1999) which is a possible reason for age related depletion of nigral dopaminergic 
neurons at a faster rate compared to other brain neuron populations (Schipper 
2004). Thus it is suggested that HO-1 expression in aging brain is indicative of 
an increased and ongoing oxidative stress.
1.7.1. Alzheimers disease
Alzheimers disease (AD) is an aging related dementia which features progressive 
neuronal degeneration, gliosis, and the accumulation of intracellular 
neurofibrillary tangles (NFT) and extracellular deposits of fibrillar amyloid 
(senile plaques) in nuclei of the basal forebrain, hippocampus and associated 
cortices (Selkoe, 1991). Implicated in the pathogenesis of this disease are
38
increased deposition of redox-active iron (Sayre et al., 2001), chronic oxidative 
stress and mitochondrial dysfunction (Schipper, 2004; Casley et al., 2002; 
Mattson, 2002).
Increased HO-1 expression has been observed in proven sporadic AD patient 
brains compared to non-demented control (Schipper et al., 1995). Co- 
immunostaining for HO-1 and tau- 2  has revealed colocalisation of HO-1  and the 
NFT associated with the AD brain (Smith et al., 1994) and senile plaques from 
both AD and control brain were also noted to be immunopositive for HO-1 and 
p-amyloid, this was in plaques (Schipper et al., 1995). Reasons for this 
pronounced upregulation of HO-1 in this condition are generally thought to be an 
antioxidative defense mechanism, one study has suggested that HO-l/tau 
interactions may prevent pathological hyperphosphorylation of tau and NFT 
formation (Takeda et al., 2000). However it has also been shown that in rat 
astroglia, upregulation of HO-1 activity resulting from exposure to exogenous 
amyloid peptide facilitates the sequestration of iron by the mitochondrial 
compartment (Ham & Schipper, 2000). Thus continued overexpression of HO-1 
could result in abnormal cerebral iron mobilization and mitochondrial damage, 
both of which have been associated with AD as already mentioned. Excessive 
HO-1 derived CO could also have a part to play in the pathogenesis of AD in that 
it could contribute to development of cognitive (Liebson & Albert, 1994), 
olfactory (Doty, 1991) and neuroendocrine (Sapolsky, 1992) disturbances 
characteristic of AD by increasing cyclic guanosine monophosphate in olfactory 
neurons (Verma et al., 1993), affecting the secretion of corticotropin-releasing 
hormone (Parkes et al., 1994), perturbing central vaso-regulatory mechanisms
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(Marks et al., 1991) and modulating hippocampal long term potentiation 
(Stevens & Wang, 1993; Zhou etal., 1993).
1.7.3. Parkinsons disease
Parkinsons disease is a movement disorder with an onset usually after 65 years of 
age. Symptoms include resting tremor, rigidity, hypokinesia and postural 
instability (Schipper 2004). The disease is characterised by progressive 
degeneration of dopaminergic neurons in the substantia nigra pars compacta and 
formation of a-synuclein-containing fibrillar inclusions (Lewy bodies) within 
this cell population. (Schipper 2004). Abnormally high levels of tissue iron have 
been reported in substantia nigra and basal ganglia of PD patients, and this may 
serve to generate ROS in this disease by reducing H2O2 to the hydroxyl radical 
and behaving as a nonenzymatic peroxidase activity capable of oxidizing 
dopamine and other catechols to toxic semiquinone intermediates (Riederer et 
al., 1989; Jellinger et al, 1990; Schipper et al., 1991; Morris & Edwardson, 
1994; Jenner & Olanow, 1998). Dysfunction of dopaminergic neurons is a 
major focus in studies of PD, but it is suggested that activation of glial cells may 
play an important role in the initiation and progression of cell death (Hirsch et 
al., 1998; McNaught & Jenner, 2000a; McNaught & Jenner, 2000b). Indeed it 
has been shown that excessive nigral iron seems to be predominantly deposited 
within astrocytes, migcroglia, macrophages and microvessels (Schipper, 2004). 
Upregulation of HO-1 expression has been well documented in PD. Cytoplasmic 
Lewy bodies from PD specimens have been shown to exhibit prominent HO-1 
immunoreactivity (Castellani et al., 1996; Schipper, 2004) , expression of HO-1 
in the neuropil of the PD nigra was generally more pronounced than in control
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counterparts (Schipper et al., 1998) and in vitro physiological concentrations of 
dopamine (lpM ) used to treat astroglial cultures rapidly upregulated HO-1 gene 
transcription and enzyme activity causing mitochondrial oxidative stress and 
permeabilistion of the mitochondria to nontransferrin iron and other transition 
metals (Schipper , 2004). It is suggested that pathological expression of HO-1 in 
astrocytes within the PD nigra may provide an explanation for the perturbed iron 
homeostasis and oxidative mitochondrial damage observed in affected tissues 
(Beal, 2003).
1.7.4. Multiple Sclerosis
Multiple sclerosis (MS) is a disease of the central nervous system characterised 
by dysregulation of cytokine production, inflammation, oligodendroglial 
degeneration , multifocal demyelination, axonal degeneration and astrogliosis 
(Schipper, 2004). There is evidence that aberrant iron deposition and oxidative 
stress have a role to play in the pathogenesis of this disease (Levine & 
Chakrabarty, 2004). GFAP positive astrocytes expressing HO-1 in spinal cord 
plaques from MS patients were considerably greater than that in the spinal white 
matter of normal subjects (Mehindate et al., 2001) and proinflammatory 
cytokines secreted in MS-affected tissues promoted sequestration of non­
transferrin derived 55Fe by astroglial microglia, which could be prevented by co- 
administration of HO inhibitors, mitochondrial permeability transition pore 
blockers or antioxidants (Mehindate et al, 2001). It is suggested that 
overexpression of HO-1, caused by inflammatory cytokines (Mehindate et al., 
2001) or myelin basic protein (Businaro et al., 2002) could contribute to
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inappropriate pathological iron mobilisation and electron transport chain defects 
seen in the vicinity of MS plaques (Lu et al., 2000).
1.8. Inducible nitric oxide synthase, NO and neurodegeneration
As discussed in the previous section HO-1 expression is associated with many 
disease states. In the neurodegenerative diseases mentioned (at least) another 
common feature is pathological production of NO via activation of inducible 
nitric oxide synthase (iNOS). Physiologically NO is generated by NO synthase 
(NOS; EC 1.14.13 .39). There are three known isoforms of this enzyme, neuronal 
NOS (nNOS), inducible NOS (iNOS) and endothelial NOS (eNOS) (for review 
see Alderton et al., 2 0 0 1 ). These enzymes catalyse, in the presence of molecular 
oxygen, tetrahydrobiopterin and other cofactors, the conversion of arginine to 
NO plus citrulline (Lincoln et al., 1997). NO has been ascribed a number of 
important biochemical roles within the central nervous system including cGMP 
formation following the activation of soluble guanylyl cyclase and the regulation 
of the glycolytic enzyme glyceraldehydes-3-phosphate dehydrogenase 
(Garthwaite et al., 1988; Heales et al., 1997). However NO is a free radical and 
in many biological systems has a short half life due to its reactivity with other 
intracellular constituents, such as superoxide (Beckman et al., 1993), this 
reaction forms the reactive nitrogen species peroxynitrite (ONOO) which is 
cytotoxic (Lipton et al., 1993) as discussed previously. Excessive production of 
NO and its ability to form ONOO' have been implicated in the pathophysiology 
of a number of neurodegenerative diseases, where mitochondrial damage is a 
factor, including PD, AD, MS, ischaemia and amylotrophic lateral sclerosis 
(Heales et al., 1999; Stewart & Heales, 2003).
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NO-mediated inhibition of complex I has been demonstrated in some studies 
(Stadler et al., 1991; Geng et al., 1992) although it has been reported that this 
inhibition is due to ONOO' rather than NO (Cassina & Radi, 1996; Riobo et al., 
2001). However, other groups have reported that complex I is relatively resistant 
to NO/ONOO' mediated inhibition (Bolanos et al., 1994; Bolanos et al., 1995; 
Stewart et al., 1997). A number of factors may be responsible for this apparent 
discrepancy of results; concentration of mitochondria used, respiratory substrates 
used, GSH status of cells or mitochondria used or type of NO donor (Stewart & 
Heales, 2003).
The activities of complex II and complex III are often assayed together using a 
single assay (King, 1967), and mitochondrial complex II + III has been reported 
to be vulnerable to NO/ONOO' exposure (Bolanos et al., 1994; Bolanos et al., 
1995, Stewart et al., 1997).
NO is able to reversibly and irreversibly inhibit complex IV (Keilin & Hartree 
1939). NO reversibly inhibits by binding to complex IV in competition with 
oxygen (Stevens et al., 1979). Irreversible inhibition has been reported following 
prolonged NO exposure of mitochondria (Poderoso et al., 1996) and cells 
(Bolanos et al., 1996). It is reported that exposure of astrocytes to cytokines 
which may be elevated in inflammatory neurodegenerative disease, for example 
IFNy causes generation of reactive nitrogen species, leading to inhibition of the 
mitochondrial respiratory chain (Bolanos et al., 1994).
1.9. Interactions between the HO and iNOS enzyme systems
There are obvious similarities between the HO and NOS systems. Both have 
inducible and constitutive forms. The inducible form of NOS is is responsive to
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certain of the stimuli which induce HO-1 (Maines, 1997), although HO-1 is 
known to have many more inducers. Both systems produce gases that have 
important physiological functions, and both these gases by their affinity for the 
haem molecule are able to bind soluble guanylyl cyclase and cause it to activate 
cGMP (see review, Alderton et al., 2001). Both of the constitutive forms are 
regulated by the adrenal glucocorticoids, although in opposite ways, expression 
of HO being upregulated and NOS downregulated (Maines, 1997).
It is recognized that these two enzyme systems have regulatory effects on each 
other, with many reports that NO upregulates HO-1 production (Bouton & 
Demple, 2000, Datta & Lianos, 1999, Foresti et al.,\991) though interestingly 
Willis et al., (1995) report that the NO donor sodium nitroprusside (SNP) 
reduced HO activity in both brain and spleen. HO can modulate NOS activity 
and therefore production of NO in a number of ways. Increased HO-1 activity 
caused by NO production could degrade the haem located in the active site of 
NOS or deplete available haem for de novo synthesis of NOS (Maines, 1997). 
Iron released by HO action could further inhibit NOS by inhibiting its nuclear 
transcription. Also both enzymes require NADPH as a co-factor, and the 
subsequent reduction of biliverdin by biliverdin reductase also utilizes NADPH, 
which could shift competition for electrons in favour of the HO pathway 
(Maines, 1997). NOS activity can also be directly affected by inhibition by CO 
binding to the haem active site. Studies have shown that exogenous CO inhibits 
both macrophage and rat cerebellar NOS activity (White & Marietta, 1992). It 
has been shown though, that the effect that CO has can depend on the amount of 
CO in the system. Thorup et al., (1999) report that high levels of CO inhibit NOS
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activity and NO generation whereas lower concentrations induce release of NO 
from intracellular pools.
The links between the HO and NOS enzyme systems lead to questions about the 
role that HO may play in neurodegeneration. As mentioned previously, CO binds 
to cytochrome c oxidase (Piantadosi, 2002) due to its affinity for the haem 
moiety. Thus CO, like NO, can cause increased electron leakage and hence 
formation of the superoxide anion, leading to oxidative stress, mitochondrial 
inhibition and ATP depletion. It has been documented that CO poisoning can 
cause oxidative stress (Piantadosi et al., 1997; Thom, 1990; Thom et al., 1997; 
Zhang & Piantadosi, 1992). Mitochondrial damage caused by NO has been 
implicated in various neurodegenerative disorders (Heales et al., 1999). In these 
disorders upregulation of HO-1 is also reported (Schipper, 2000), thus leading to 
a possible rise in endogenous CO levels. In this case could it be possible that HO 
derived CO is responsible for a proportion of the mitochondrial damage 
previously attributed to NO? We know that the capacity of the brain to generate 
CO may exceed its capacity to generate NO (Maines, 1993). Moreover, Thom et 
al., (1997) report that CO competes for intracellular sites that normally bind NO, 
which increases the steady state level of unbound NO available to undergo 
reactions with superoxide. So CO may be likely to potentiate oxidative stress by 
binding to cytochrome c oxidase and also make available NO, thus increasing the 
possibility of nitrosative stress.
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l.lO.The aims of the thesis
In view of the suggestion that HO-1 induction can act in both a beneficial and a 
deleterious way within the cell and the fact that upregulation of HO-1 is reported 
in many neurodegenerative diseases, this thesis has examined the effects of HO 
induction in rat astrocytes and interactions with the NO/iNOS system. As 
previously discussed induction of iNOS in rat astrocytes with IFNy/LPS causes 
inhibition of complex IV of the ETC; since it has already been shown that 
IFNy/LPS also induce HO-1 expression (Kitamura et al., 1998) this thesis will 
examine whether this expression is accompanied by enzyme activity, and if so 
what is the consequence for the cell if this activity is augmented or inhibited. The 
thesis will be set out as follows:
1) Establishment and validation of an assay to determine HO activity in rat 
astrocytes.
2) Induce HO-1 activity and expression in rat astrocytes and examine the 
effects on the ETC, GSH and nitrite/nitrate status
3) Induction of iNOS activity and examination of the effects of this on HO-1 
expression and HO activity
4) Investigation of the consequences of manipulating the HO-1 status of 
iNOS activated astrocytes and the effects this has on NO- mediated 
respiratory chain inhibition, HO activity and GSH status.
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Chapter 2.
General Materials and Methods
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2.1 Materials.
Unless otherwise stated all chemicals were of analytical grade and purchased 
from Sigma-Aldrich Company Ltd (Poole, UK), or VWR International Ltd 
(Leicester, UK). In particular:
Deoxyribonuclease 1 (from bovine pancreas, EC 3.1.21.1), Earle’s Balanced Salt 
Solution, Hank’s Balanced Salt Solution, bovine serum albumin, L-glutamine, 
antibiotic antimycotic solution (lOOx), trypsin-EDTA solution (lOx, porcine 
trypsin), rotenone, coenzyme Qi, antimycin A and L-N6 -(L-iminoethyl) lysine 
hydrochloride (L-NIL) were purchased from Sigma-Aldrich Company Ltd 
(Poole, UK).
Tissue culture plastics and spectophotometric grade chloroform were purchased 
from VWR International Ltd (Leicester, UK).
Trypsin (from bovine pancreas, EC 3.4.21.4), oxidised cytochrome c (from horse 
heart) and glucose-6 -phosphate dehydrogenase (EC 1.1.1.49) were purchased 
from Roche Diagnostics (Lewes, UK).
Minimal essential medium and foetal bovine serum were purchased from 
Invitrogen, (Paisley, UK).
Hemin was purchased from Frontier Scientific Europe Ltd (Lancashire, UK).
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Tin protoporphyrin IX (SnPPIX) and zinc protoporphyrin IX (ZnPPIX) were 
purchased from Affiniti Research Products Ltd (Exeter, UK).
Sephadex G-25M (PD-10 columns; 3.5ml elution) used to remove ascorbate 
from reduced cytochrome c were bought from Amersham Biosciences (Little 
Chalfont, UK).
The nitric oxide (NO) donor, (Z)-l-[2-aminoethyl)-N-(2- 
ammonioethyl)amino]diazen-l-ium-l,2-diolate (DETA-NO) was purchased from 
Alexis Biochemicals (Nottingham, UK)
Antibodies to haem oxygenase-1 (HO-1) and inducible nitric oxide synthase 
(iNOS) were purchased from Bioquote Ltd (York, UK).
The mouse monoclonal anti-glial fibrillary acidic protein was purchased from 
Stemberger Monoclonals Inc. (Lutherville, Maryland, USA).
The Bio-Rad protein assay kit and 1 2 % TRIS-HC1 mini prep gels were 
purchased from Bio-Rad Laboratories (Hercules, California, USA)
Interferon gamma (IFNy) was purchased from CN Biosciences (California, 
USA).
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2.2. Tissue culture
2.2.1. Cell Culture Media Composition
Solution A was composed of Earle’s Balanced Salt Solution (EBSS) containing 
deoxyribonuclease I (75 KU/ml), 1% vol/vol antibiotic antimycotic solution (10 
units/ml penicillin, lgg/ml streptomycin and 2.5ng/ml amphotericin B) and 
3mg/ml bovine serum albumin (BSA).
Solution B was composed of solution A supplemented with 112.5 KU/ml 
deoxyribonuclease I and 27.5 units/ml trypsin.
Astrocyte medium was composed of L-valine based minimal essential media 
(MEM) supplemented with 2mM L-glutamine , 10% (v/v) foetal bovine serum 
and 1% (v/v) antibiotic antimycotic solution.
2.2.2. Animals
Pregnant Wistar rats were purchased from A.J. Tuck and Sons Ltd. (Rayleigh, 
Essex, U.K.), fed ad libitum on a stock laboratory diet, and were maintained on a 
1 2  hour light dark cycle.
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2.2.3. Primary astrocyte culture
Primary cortical rat astrocytes were isolated from neonatal (0-2 days) Wistar rats 
by a method adapted from Tabemero et al (1993). Neonates were decapitated 
and the cortices removed. Each cortex was then held with a pair of dissecting 
tweezers and “rolled” on filter paper (Whatman Type 1) to remove blood and 
meninges and prevent the growth of fibroblasts. The cortices were then triturated 
in solution A (section 2.2.1). The triturated brain solution was then centrifuged at 
500 x g for 5 minutes at 4°C. The supernatant was discarded and the pellet 
enzymatically digested in solution B (section 2.2.1) for 15 minutes at 37°C. 
Digestion was terminated by adding 1ml foetal bovine serum, and the astrocytes 
were pelleted by centrifugation at 500 x g for 5 minutes at 4°C. The resulting 
pellet was resuspended in 10ml of solution A and debris was allowed to settle out 
for ~ 5 minutes. The supernatant was carefully removed with a 1ml Gilson 
pipette and centrifuged at 500 x g for 5 minutes at 4°C. The pellet was 
resuspended in astrocytic medium (section 2 .2 .1) and passed through nylon 
gauze (lOOpM pore size) to remove any remaining cell debris. Astrocytes were 
plated in 80-cm2 flasks ( 2  heads per flask) and cultured in astrocytic medium in a 
Heraeus incubator (95% air/5% C02) at 37°C, and medium was changed every 
third day.
2.2.3.1 Passage of astrocytes
Astrocytes were passaged on day 7 when they reached confluence. Cell media 
was removed and cells washed with Hank’s Balanced Salt Solution (HBSS), and
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incubated with 10ml trypsin/EDTA solution (0.5% (w/v) trypsin, 0.2% (wt/vol) 
EDTA) for 5 minutes. Trypsinisation was terminated by the addition of 5% (v/v) 
foetal bovine serum, and the astrocytes pelleted by centrifugation at 500 x g for 5 
minutes at 4°C. Astrocytes were then resuspended in astrocytic medium (to a 
volume twice that before trypsinisation) and cultured in flasks for a further 6  
days as described previously.
2.2.3.2 Plating and treating of astrocytes
Astrocytes (Figure 2.1.) that were to be treated in 6 -well plates were removed 
from the flasks on day 13 as described above, (section 2.2.3.1.) and resuspended 
in astrocyte media. The cells were counted and then seeded onto poly-l-lysine 
coated (lOpg/ml) plates at a density of 1.04 x 105 cells/cm2. The cells were then 
incubated for 18-24 hours to allow them to attach. For treatment, media was 
removed and replaced with fresh media containing specified treatments for 
defined periods of time. For the HO assay cells were treated in flasks. On day 13 
media was removed and replaced with fresh media containing specified 
treatments for defined periods of time.
2.2.3.3 Harvesting of cells
Following treatment in 6 -well plates, cells were harvested by trypsinisation. 
Media was removed and cells washed with 1ml HBSS. 1ml trypsin/EDTA 
solution was added and incubated at room temperature for 2  minutes. 
Trypsinisation was terminated by the addition of lOOpl foetal calf serum (FCS).
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Figure 2.1. Phase contrast image of confluent primary rat astrocytes at day 14 of 
culture. 1 Ox objective.
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Cells were collected and centrifuged at 500 x g for 5 minutes at 4°C. Pellets 
were then resuspended in appropriate buffer for assay and if necessary snap 
frozen in liquid nitrogen and stored at -70°C until assay. For HO assay, media 
was removed from flasks and cells washed with 10ml HBSS. Cells were then 
scraped using a long handled cell scraper. Cells and HBSS were collected and 
centrifuged at 500 x g for 5 minutes at 4°C. Pellets were resuspended in 500gl 
HO buffer (2 mM MgCl2, lOOmM K2HP04, lOOmM KH2P 0 4 pH 7.4), frozen in 
liquid nitrogen and stored at -70°C until assay.
2.2.3.4. Immunostaining of astrocytes
To determine the astrocytic content of cultures, staining for glial fibrillary acidic 
protein (GFAP) was used. GFAP is a well-established marker for astrocytes as it 
is the principal intermediate filament of mature astrocytes in the central nervous 
system (Eng et al., 2000). Cells were seeded at a density of approximately 1.3 x 
103 cells/cm2 onto 25mm glass cover slips pretreated with poly-l-lysine, and 
allowed to attach for 24 hours. After this time the astrocyte media was removed 
and the cells were washed 3 times with phosphate buffered saline (PBS; 0.14M 
NaCl, 2mM KH2P 0 4, pH 7.4). Astrocytes were then fixed by addition of 1ml ice- 
cold (-20°C) methanol per well for 5 minutes. The methanol was removed and 
the cells washed with PBS three times. Each cover slip was then incubated in 
lml l%(v/v) horse serum for 30 minutes (room temperature) in order to prevent 
non-specific binding before being washed three times with PBS once more, lml 
of mouse derived primary antibody to GFAP (1:2000 dilution in PBS) was then 
added to the coverslips before overnight incubation at 4°C. One coverslip was
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incubated with PBS only as a blank control. After incubation the coverslips were 
washed three times with PBS , and then incubated with lml of secondary 
antibody (fluorescein isothiocyanate (FITC)-conjugated secondary anti-mouse 
immunoglobulin-G antibody (1:500 dilution in PBS) for 1 hour at room 
temperature. Non-specific binding of the secondary antibody was determined by 
incubating it with astrocytes which had not been exposed to the primary 
antibody. Once more coverslips were washed three times with PBS and then 
incubated with lml 0.01% 4’-6-diamidino-2-phenylindole (DAPI) in the dark for 
10 minutes in order to stain cell nuclei and ascertain cell numbers. The coverslips 
were washed 3 times finally and mounted on glass microscope slides (BDH Ltd, 
76 x 26 mm) using lOpl Cytoflour (Cytoflour Ltd. London, UK).
Digital imaging of cells was performed using a Zeiss 510 CLSM laser scanning 
confocal microscope (Solent Scientific, Portsmouth, UK) equipped with a 40x oil 
immersion quartz objective lens and a 20x quartz objective lens. The 
fluorescence of the FITC-conjugated antibodies was imaged by illuminating cells 
using the 488 nm emission line of a helium-neon laser, and the fluorescence 
signal was collected at wavelengths longer than 505 nm. In order to image DAPI 
fluorescence, cells were illuminated using the 351 nm laser line of an argon laser 
and the fluorescence signal was collected at 435 and 485 nm. The microscope 
pinhole was maintained at a confocal thickness of about 5mm.
The purity of the cultures was calculated by determining the proportion of DAPI 
fluorescence containing cells that were also positive for GFAP fluorescence. 
Astrocyte cultures showed a 94 ± 2% immunopositivity against GFAP (Figure
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2.2.). No GFAP fluorescence was detected in the blank control incubated with 
the secondary antibody alone.
2.3.Enzyme assays
2.3.1 Complex I Assay (NADH: ubiquinone reductase; EC 1.6.5.3)
Complex I activity was determined as described by Ragan et al., (1987) with 
modifications. Samples (10-20pg), suspended in sucrose-Hepes buffer (0.25M 
sucrose, 2 mM Hepes pH 7.2) were freeze-thawed three times in liquid nitrogen 
and mixed with assay buffer (8 mM MgCl2, 20mM KH2P 0 4, 20mM K2HPO4, pH 
7.2), 2.5mg/ml BSA (fatty acid free), ImM KCN and 0.15mM NADH, in lml 
cuvettes. The reaction mixture was incubated at 30°C for 2  minutes prior to the 
addition of 50pM coenzyme Qi. Enzyme activity was measured at 30°C by 
following the oxidation of NADH to NAD^ for 5 minutes (NADH extinction 
coefficient 6.81 x 103 M^cm'1; total volume lml; path length 1cm) using an 
Uvikon 941 spectrophotometer. Each sample was measured against a blank 
which contained sample and all substrates except coenzyme Qi. After 5 minutes 
20pM rotenone was added to the sample cuvettes which were measured for a 
further 5 minutes in order to measure rotenone insensitive NADH oxidation. 
Complex I activity was calculated by subtracting the rotenone insensitive NADH 
oxidation rate from total NADH oxidation rate (units = nmol/min/mg protein). 
Complex I activity was proportional to protein between 5 and 20pg protein (R 
0.9833).
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Figure 2.2. Image of glial fibrillary acidic protein positive astrocytes 
(green). Cell nuclei were stained with 4\6-Diamidino-2-phenylindole (DAPI) 
(blue) Bar = 10pM.
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2.3.2. Complex II/III assay (succinate cytochrome c reductase; EC 1.8.1.3)
Complex II/III activity was determined in a linked assay as described by King 
(1967). Electrons are transferred through complex II by the oxidation of 
succinate , to ubiquinone (CoQi), this reduces CoQi to ubiquinol. Complex III 
reduces cytochrome c by the transfer of electrons from ubiquinol, and this 
simultaneously oxidises ubiquinol back to CoQi. Activity therefore was 
measured by the reduction of cytochrome c at 550nm (cytochrome c extinction 
coefficient 19.2x103 M^cm'1; total volume lml; path length 1cm) using a Uvikon 
941 spectrophotometer. Samples (10-20mg protein; freeze- thawed 3 times in 
liquid nitrogen) were mixed with assay buffer (lOOmM KH2PO4, lOOmM 
K2HPO4, pH 7.4), 0.3nvM EDTA, ImM KCN, and IOOjliM oxidised cytochrome 
c (from horse heart) in a cuvette. The reaction was started by the addition of 
20mM succinate and enzyme activity was measured at 30°C for 5 minutes. At 
this time lOpM antimycin A was added and the antimycin A insensitive rate of 
cytochrome c reduction was measured for a further 5 minutes. Complex II/III 
activity was calculated by subtracting the antimycin A insensitive cytochrome c 
reduction rate from total cytochrome c reduction rate (units = nmol/min/mg 
protein). Each sample was measured against a blank which contained all 
substrates except succinate. Complex II/III activity was proportional to protein 
between 5 and 25pg protein (R2 0.9833).
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2.3.3. Complex IV assay (cytochrome c oxidase; EC 1.9.3.1)
2.3.3.1. Reduction of oxidised cytochrome c
Ascorbate crystals were added to oxidised cytochome c (0.8mM from horse 
heart) and a colour change was observed from dark red to light red. The 
ascorbate was removed from the reduced cytochrome c by passing it through a 
PD10 gel filtration column (column equilibrated by first washing with ~ 50ml of 
lOmM phosphate buffer; lOmM KH2P 0 4, lOmM K2HP04 pH 7.0) Concentration 
of reduced cytochrome c was determined by mixing 50pl reduced cytochrome c 
with 950pl H20  in sample and reference cuvette. The cuvettes were “blanked” 
against each other at 550nm and ImM potassium ferricyanide was added to the 
reference cuvette to re-oxidise the cytochrome c\ and the absorbance of the 
sample cuvette noted (cytochrome c extinction coefficient l ^ x lO ^ ^ c m '1; total 
volume lml; path length 1cm).
2.3.3.2. Measurement of complex IV activity
Complex IV activity was determined following the method of Wharton & 
Tzagoloff (1967). In a sample and reference cuvette, assay buffer (lOmM 
KH2P 0 4, lOmM K2H P04, pH 7.0) and 50pM reduced cytochrome c were 
mixed, and the sample cuvette “blanked” against the reference. ImM potassium 
ferricyanide was added to the reference cuvette, to oxidise the cytochrome c. The 
reaction was started by adding sample to the sample cuvette (10-20pg protein; 
freeze-thawed three times in liquid nitrogen). The oxidation of cytochrome c was
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followed for 5 minutes at 30°C using a Uvikon 941 spectrophotometer 
(cytochrome c extinxtion coefficient 19.2xl03 M^cm'1; total volume lml; path 
length 1cm). Since complex IV activity is dependent on the concentration of 
cytochrome c, complex IV activity is expressed as the first order rate constant k 
per minute per mg of protein. Activity was determined by noting the highest 
positive absorbance following sample addition (t = 0 minutes), and the 
absorbance every minute after that for 3 minutes, k was calculated by: ((In (A550 t 
= o/ A550 t = n) / number of minutes)/ protein concentration. The rate constant for 
each sample was taken as the mean of k at 1,2 and 3 minutes. Complex IV 
activity was proportional to protein between 15 and 30pg of protein (R2 0.9905).
2.3.4. Citrate Synthase Assay (EC 4.1.3.7)
Citrate synthase (CS) activity was determined using a method described by 
Shepherd and Garland (1969). Sample (10-20 pg protein; freeze-thawed three 
times in liquid nitrogen) was mixed with buffer (lOOmM Tris, 0.1% (v/v) Triton 
X-100, pH 8.0), O.lmM acetyl coenzyme A, and 0.2mM 5,5’ dithio-bis- 
(nitrobenzoic acid)(DTNB) in a cuvette (total volume 1 ml, path length 1 cm). The 
reaction was started by the addition of 0.2mM oxaloacetate and activity 
measured using a Uvikon 941 spectrophotometer for 5 minutes. Activity was 
measured at 412nm and at 30°C (DTNB extinction coefficient 13.6xl03 M_1cm" 
1). Samples were run against a reference cuvette which contained sample and all 
substrates except oxaloacetate. Citrate synthase activity was linear with respect 
to protein between 5 and 25 pg protein (R2 0.9822).
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2.3.5. Lactate Dehydrogenase Assay (EC 1.1.1.27)
Lactate dehydrogenase activity was determined spectrophotometrically as 
described by Vassault (1983). LDH released into lml of cell culture media 
during the treatment period, by lxlO6 astrocytes, was used as an index of cell 
viability. Assay buffer (lOOmM KH2P 04, lOOmM K2HP04, 170mM sodium 
pyruvate, pH 7.5) was mixed with 0.16mM NADH in the sample and reference 
cuvettes. Absorbance was then measured using a Uvikon 941 spectrophotometer 
for 5 minutes at 340nm after the sample and reference cuvettes had been 
“blanked” against each other. Absorbance was measured at 30°C (NADH 
extinction coefficient 6.8lx l0 3 M'1 cm"1; total volume lml; path length 1cm). The 
% release of LDH into culture medium was calculated as: LDH activity in media/ 
LDH activity in media + cells (Bolanos et al., 1995).
2.4. Total Nitrate and Nitrite
In order to provide an indication of NO production in cells it is possible to 
measure the NO breakdown products, nitrite and nitrate using the Griess assay 
(Green et al., 1982). Phenol red free media must be used in order that the phenol 
red does not interfere with the colourmetric reaction.
The Greiss assay is based on the reaction between nitrite and sulphanilamide in 
acidic solution which forms an intermediate diazonium salt that couples to N-(l- 
napthyl)ethylenediamine to yield a purple azo derivative that can be monitored 
by absorbance at 540nm. Standards of sodium nitrite and sodium nitrate
61
(0,10,20,30,40,50,100pm) were made up in phenol red-free medium. Another set 
of standards were made up in phenol red-free medium that contained 1 0 0 pm 
hemin, in order that absorbance due to hemin could be taken into account.
50pl samples and standards were pipetted into 96 well plates in duplicate. Since 
the Griess reagents only measure nitrite it was then necessary to convert any 
nitrate present to nitrite in order to accurately measure all breakdown products. 
This was done using nitrate reductase (EC 1 .6 .6 .2) (from Aspergillus, Roche 
Diagnostics, Lewes, UK). lOpl of each of the following reagents were added to 
each well (final concentrations): 5pM flavin adenine dinucleotide disodium salt 
(FAD), lOOpM NADPH and O.lunits/ml nitrate reductase. The plate was then 
incubated at 37°C for 15 minutes in the dark. lOpl of each of the following 
reagents were then added to each well (final concentrations): 1 0 0  units/ml lactate 
dehydrogenase and lOOmM sodium pyruvate in order to remove excess NADPH 
via oxidation to prevent it interfering with detection with the detection of nitrite 
by the Griess reagents (Medina A and Nicholas DJD (1957), in Green et al., 
1982). The plate was then incubated at 37°C for a further 5 minutes. The Griess 
reagents were prepared immediately before addition by combining 0 .1% (w/v) 
N-(l-naphthyl)ethylenediamine dihydrochloride in water and 1% sulphanilamide 
in 5% (w/v) H3PO4 . lOOpl Griess reagent was added to each well and the plates 
were incubated in the dark for 15 minutes at room temperature. The absorbance 
of each well was read at 540nm using a spectrophotometric plate reader 
(SpectraMax Plus®, Molecular Devices, Wokingham, UK). The action of nitrate 
reductase was confirmed each time the assay was performed by using two 
standard curves to ensure that sodium nitrate had been reduced to sodium nitrite. 
(Figure 2.3.)
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Figure 2.3. Greiss assay standard curve
The representative nitrite standard curve shows the absorbance of both nitrite 
standards (♦) and the reduced nitrate standards (■).
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2.5. Western Blot analysis
Cells for western blot analysis were lysed on ice with lysis buffer (0.27M 
sucrose, 20mM Tris, ImM EDTA, ImM EGTA, lOmM Na p glycerophosphate, 
ImM Na orthovanadate, 5% glycerol, 1% triton-x 100 pH 7.4) for 10 minutes , 
then sonicated for 30 seconds. Each sample was then centrifuged at 14000g for 
10 minutes. The resulting supernatant was used for HO-1 or iNOS protein level 
determination. Equal amounts of protein (10pg) were loaded onto a 12% TRIS- 
HCL ready gel and separated by sodium dodecylsulphate-polyacrylamide gel 
electrophoresis (180V for 1 hour). The proteins were transferred to a 
nitrocellulose membrane using a semi-dry blotting system (100mA for 1 hour) 
(Figure 2.4.). The membrane was checked for protein transfer using Ponceau red. 
Unspecific binding sites on the membrane were blocked using 5% skimmed milk 
blocking buffer ((5% skimmed milk powder in Tris buffered saline -  Tween 20 
(20mM Tris base, 137mM NaCl, 0.05% Tween-20)pH 7.6)) (TBS-T) for 1 hour 
at room temperature. Membranes were then probed with polyclonal HO-1 or 
iNOS antibodies (Stressgen, Victoria, Canada) for 2 hours at room temperature 
(HO-1 1:4000, iNOS 1.5000, in TBS-T). The membrane was washed 3 x 10 
minutes in TBS-T and then incubated with the secondary antibody, ECL Anti­
rabbit IgG, peroxidase-linked species specific whole antibody from donkey 
(Amersham Biosciences UK Ltd, Buckinghamshire, UK) (1:4000 dilution).
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Figure 2.4. Semi-dry transfer of proteins after SDS-PAGE
Schematic to show the “transfer sandwich” for a semi-dry Western blot. Six 
sheets of blotting paper cut to size were soaked briefly in transfer buffer (48mM 
Tris/HCL, 39mM glycine, 0.0375% SDS, 20% MeOH, pH 9.2). Three sheets of 
blotting paper were assembled on top of each other on the Trans-Blot semi-dry 
transfer cell (Bio-Rad). The gel was soaked in transfer buffer and placed on top 
of the first three sheets of blotting paper. A piece of nitrocellulose membrane 
(Hybond ECL Nitrocellulose, Amersham) was cut to size, soaked in transfer 
buffer and placed carefully on top of the gel ensuring no air bubbles were 
created. The last three sheets of blotting paper were then placed on top of the 
membrane. The lid of the transfer cell was closed securely, compressing the 
“sandwich” and a current applied across the cell, 0.1A for 1 hour to effect protein 
transfer.
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Protein-antibody complexes were detected using an ECL plus western blotting 
detection system (Amersham Biosciences UK Ltd. Equal protein loading was 
confirmed by probing the membrane with a (3- actin antibody (Sigma). 
Molecular masses were determined by using Bio-Rad Precision Plus protein 
standards.
2.6. GSH Quantitation 
2.6.1 Chromatography of reduced glutathione
Reduced glutathione (GSH) was measured using reverse phase HPLC with 
electrochemical detection (Figure 2.5) based on the method of Reiderer et al., 
(1989). Sample (20jnl) was injected by a Kontron HPLC 360 autosampler 
(Watford, U.K) through a guard column (octadecasilyl; 3mm x 10mm) to remove 
any debris, and resolved using a reverse-phase Techsphere octadecasilyl column 
(particle size 5pm, 4.6mm x 250mm) which was maintained at 30°C by a column 
heater (Jones Chromatography; Glamorgan, U.K.). Mobile phase was 15mM 
orthophosphoric acid prepared in de-ionised water that had been purified to 
electrical resistance of < 18 MQ.cm-1 using a milli-Q apparatus. This was 
degassed by a DEG-1033 degasser (Kontron Instruments). Flow rate was 
maintained at 0.5ml/min by a Jasco PU-1580 pump (Great Dunmow, U.K).
66
Guard column
Pump
0.5ml/min
Column heater
Waste
Degasser Autosampler
Reverse-phase 
HPLC column
E2
Mobile
phase
Integrator
Figure 2.5. Scheme to illustrate the equipment used to measure GSH by 
reverse-phase HPLC and electrochemical detection.
El = upstream electrode; E2 = downstream electrode.
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2.6.2. Electrochemical detection of GSH
Following separation by the column GSH was detected by an ESA 5010 
analytical cell containing an upstream and downstream electrode (ESA 
Analytical; Aylesbury, UK). The upstream electrode was set at + lOOmV to 
screen out molecules with a lower oxidation potential than GSH. In order to 
determine the optimal potential to detect GSH at the downstream electrode GSH 
standards (lOpM) were injected and measured at various downstream electrode 
potentials (Figure 2.6.). GSH detection by the downstream electrode reached a 
plateau between 800mV and 850mV. The current generated by the oxidation of 
GSH was proportional to the amount of GSH, which was detected at the 
downstream electrode. This was recorded as a chromatogram on a 
Thermoseparation Products chromejet integrator (Anachem; Luton, U.K).
2.6.3. Sample preparation
GSH standards (l-10pM) were prepared in 15mM orthophosphoric acid and 
stored at -70°C. Samples resuspended in HBSS were diluted 1:1 (vol/vol) with 
15mM orthophosphoric acid in order to extract GSH. Samples were then 
centrifuged for 5 minutes at room temperature at 14000 x g to pellet any protein. 
200pl of supernatant was sealed in Chromacol HPLC ready for injection onto the 
HPLC column. A typical GSH chromatogram is shown in Figure 2.7. Results 
were expressed nmol/mg protein. Electrochemical detection of GSH standards 
was linear between 1 and lOpM (Figure 2.8. R2 = 0.99).
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Figure 2.6. Voltamogram of GSH
GSH standards (IOjaM) were separated by reverse phase HPLC and detected by 
electrochemical detection. The upstream electrode was set at +100mV while the 
downstream electrode was set at potentials between +100 and +600mV. Optimal 
detection occurred when the downstream electrode was set at potentials between 
+800mV and +850mV.
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Figure 2.7. Chromatogram of an astrocyte sample
GSH from an astrocyte homogenate was extracted into 15mM OP A and 
quantitated by electrochemical detection following separation by reverse-phase 
HPLC.
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Figure 2.8. GSH standard curve
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2.7. Protein determination
Sample protein concentration was determined by the Lowry method (Lowry et 
al., 1951), using a Bio-Rad DC Protein Assay kit. To 200gl of sample (freeze 
thawed once; typically diluted 1/20 (v/v) in water) or BSA standards (0.2mg/ml 
in assay buffer), lOOpl of alkaline copper tartrate and 800gl of Folin-Ciocalteu 
phenol reagent was added. Samples were vortexed and incubated at room 
temperature in the dark for 20 minutes. Absorbance was measured at 750nm on 
an Uvikon 941 spectrophotometer. Sample protein concentration was calculated 
from a BSA standard calibration curve (0-200pg/ml).
2.8. Statistical analysis
Linear regression o f graphs was calculated using Microsoft excel.
Results are expressed as mean ± SEM for the number of independent cell culture 
preparations stated. Statistical significance of data was assessed using student’s t- 
test or one-way ANOVA followed by the least significant difference test, p <
0.05 was considered significantly different compared to control. Where activities 
were expressed as a ratio, such as complex activity as a ratio to citrate synthase 
activity or percentages data were first transformed (Transformation = 
arcsinV(ratio)) to yield data with a normal distribution before statistical 
evaluation. (Gegg et al., 2003).
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Chapter 3
A spectrophotometric method for 
determining haem oxygenase 
activity in astrocytes
73
3.1 Introduction
Since haem oxygenase (HO) has been identified as an enzyme of possible 
importance in the antioxidant defences of the cell, its expression and activity 
have been studied in many different cell types. Antibodies to both HO-1 and HO- 
2 have been developed and protein expression in tissues and cells has been 
widely investigated. Recently an ELISA kit has been made available to detect 
HO in tissues and cell lysates. Activity of the enzyme is also important in 
assessing its possible antioxidant properties and in recent years a number of 
different assays have been developed to measure this. Most assay methods 
measure production of one of the end products of HO action, carbon monoxide, 
bilirubin, or iron (Figure 3.1.), and are measures of total HO activity. 
Radioactive methods have been used to follow the fate of labelled carbon into 
bilirubin (14C haem to 14C bilirubin)(Laitinen & Juvonen, 1995) and iron into 
free iron (55Fe haem to 55Fe) (Ferris et al., 1999). Assays used to quantify CO 
production use gas chromatography (William Sunderman Jr. et al., 1982, 
Vreman& Stevenson, 1988).
Many groups have used the formation of bilirubin to quantify HO activity using a 
spectrophotometric method. This was reported by Tenhunen et al., in 1968 who 
first described the haem oxygenase enzyme system. This group had noted that in 
the intact organism haem and haemoglobin are converted nearly quantitatively to 
bilirubin. Suggestions were made as to how this conversion could come about, 
Lemberg (1956) suggested a coupled oxidation with ascorbate and molecular 
oxygen which in vitro leads to formation of bile pigment precursors. However
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Figure 3.1. Schematic of the haem oxygenase/biliverdin reductase reaction.
Measurable products are shown on yellow backgrounds.
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this was discounted as biliverdin produced by this method is a mixture of isomers 
whereas in vivo only the a-isomer of bliverdin is produced. Nakajima et al., 
(1963) reported an enzyme called heme a-methenyl oxygenase which was 
discounted as it had an unusual specificity and acted only on pyridine 
hemochromogen, haemoglobin-haptoglobin complex, and myoglobin but was 
non-active with hematin, oxyhemoglobin and methemoglobin. Another reason 
that this enzyme did not seem a likely candidate for that conversion was the fact 
that bone marrow and spleen which are active in haem degradation showed 
almost no activity. In 1968 Tenhunen et al., showed the production of bilirubin 
from haem via an enzymatic mechanism. This was done by incubating non­
activated liver, spleen and kidney microsomes with methaemalbumin. The 
reaction required the presence of molecular oxygen and NADPH and the reaction 
product showed absorbance in the region of 460-470nm. This product was 
subsequently confirmed as bilirubin. Although microsomes alone were active in 
converting haem to bilirubin, activity was greatly enhanced by the addition of a 
105,000 x g supernatant fraction. It was discovered that this fraction contained 
biliverdin reductase, which reduces biliverdin, the initial product of haem 
breakdown, to bilirubin. The method used by Tenhunen et al., forms the basis of 
the spectrophotometric assay still used today. This assay is routinely used in 
many laboratories and was chosen for this investigation to quantify HO activity. 
The assay requires all the components for the conversion of haem to bilirubin; 
microsomes from the cells in question, where HO is located, substrate for the 
enzyme, an NADPH generating system, a source of biliverdin reductase and 
suitable buffer.
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Aims
1. To validate this assay method for the quantitation of HO activity in primary rat 
astrocytes
2. To induce HO activity in primary rat astrocytes
3. To measure this activity using the spectrophotometric quantification of 
bilirubin.
3.2 Methods
3.2.1. Cell culture
Primary astrocytes were cultured as described in section 2.2. On day 13 the 
media was removed from flasks and replaced with 10ml media containing 
lOOpM hemin to induce HO activity. The flasks were incubated for a further 24 
hours before the cells were harvested for assay.
3.2.2. Preparation of liver cytosol as a source of biliverdin reductase
Adult male Wistar rats (200-250g) were sacrificed by cervical dislocation and the 
liver immediately perfused with ice-cold 1.15% KC1 solution to remove as much
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of the blood from the liver as possible. The liver was then removed and finely 
chopped with scissors in 1 volume of homogenizing buffer (1.15% KC1 -20mM 
Tris buffer pH 7.4). The liver was then homogenized in a teflon/glass 
homogeniser and centrifuged at 5000 x g for 20 minutes. At this time the lipid 
layer which had formed on top of the supernatant was removed and discarded 
and the supernatant transferred to a fresh centrifuge tube. The supernatant was
then centrifuged at 105,000 x g for 1 hour. Once again the lipid layer was
removed and the 105,000 x g supernatant removed to Eppendorf tubes. An 
aliquot of cytosol was removed for protein determination and the remainder 
frozen in liquid nitrogen and stored at -70°C until assay. In initial experiments 
the liver was removed and homogenised immediately without perfusion, however 
it is thought that this contributed to the lack of success in measuring HO activity 
at this time as haemoglobin in the cytosol can interfere with the assay.
3.2.3. Haem Oxygenase assay
Astrocytes were harvested (as described in section 2.2.3.3 ) and resuspended in 
500pl HO buffer ( lOOmM K2HP04, lOOmM KH2P 04, 2mM MgCl2 pH 7.4).
Samples were freeze/thawed in liquid nitrogen three times and sonicated on ice
for 10 seconds to disrupt cell membranes. A 400pl aliquot of the sample was 
mixed with the following assay components; HO buffer, rat liver cytosol (5- 
7mgs), hemin (20 pM final concentration, HO km for hemin 5pM, (Tenhunen et 
al., 1969)), glucose-6-phosphate (G-6-P) (2mM final concentration) and glucose- 
6-phosphate dehydrogenase (0.75U/ml final concentration, km for G-6-P 36pM). 
The reaction tubes were vortexed and 0.8mM NADPH was added to start the
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reaction. Tubes were incubated at 37°C in the dark for the appropriate time, and 
the reaction was stopped by adding 1ml ice cold chloroform and vortexing for 30 
seconds. Samples were centrifuged at 500 x g for 10 minutes, after centrifuging 3 
clear layers were evident in the sample tubes, a top aqueous layer, a middle layer 
which was comprised of solid lipids and cell material and a bottom organic layer 
into which any bilirubin had been extracted. The organic layer was removed to a 
quartz cuvette and the absorbance read between 464-530nm. The difference 
between the two wavelengths was calculated and HO activity was expressed in 
picomoles of bilirubin/mg/hr. (840mM-l.cm-l). The spectrophotometer was 
blanked using chloroform before each measurement.
In chloroform bilirubin has a maximal absorbance of 464nm, the HO assay uses 
464-530nm to calculate bilirubin present as 530nm is the absorption at which 
bilirubin does not have any reading so is used as the baseline. In order to check 
this a lOpM solution of bilirubin was made up in bilirubin and the absorbance 
spectra was read. At the same time lOpM chloroform solutions of hemin and 
biliverdin were made up to measure their absorbance in case they could prove to 
interfere with absorbance results.
The above method was the one used during this investigation, however a number 
of difficulties were experienced initially. Methods used by Motterlini et al., 
(1996), Maines (1996) and Iyer et al., (1998) were investigated without success 
and it became apparent on investigating the assay components that some points 
were critical to the success of the assay. Firstly, as mentioned in section 3.2.2. 
the liver must be perfused before homogenisation so as to minimise haemoglobin 
interference in the assay, chloroform must be of spectrophotometric grade (intial
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experiments were carried out using HPLC grade chloroform) and once the assay 
has been stopped with ice-cold chloroform, mixing must be extensive to extract 
bilirubin into the chloroform for measurement.
3.3. Results
3.3.1. Validation of HO assay method
Bilirubin was soluble in chloroform and absorbed maximally at around 464nm, 
there was no positive absorbance beyond 530nm (Figure 3.2.). Neither hemin 
nor biliverdin were soluble in chloroform (20pM and lOfiM respectively).
Confluent astrocytes in 80cm3 flasks were treated with lOOpM hemin for 24 
hours. Cells were harvested as described in section (2.2.2.3.) and pooled into HO 
assay buffer. The protein concentrations were determined and samples were 
diluted in buffer to concentrations of 0.15, 0.25, 0.3, 0.5 and 1 mg/ml. Samples 
were then assayed for HO activity (for 1 hour as described in Motterlini et al.,
(1996)) as described in section 3.2. Using this method activity was found to
•  •  •  2increase linearly with protein concentration, up to lmg protein per ml (R =
0.9956, n=3).
In order to further validate the assay for use in rat astrocytes as isolated by the 
method described in section (2.2.3.) a time course experiment was carried out. 
Confluent astrocytes in 80cm3 flasks were treated with lOOpM hemin for 24
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Figure 3.2. Bilirubin spectra
lOpM bilirubin was dissolved in chloroform and the spectra recorded. Maximal 
absorbance is shown at around 464nm, no positive absorbance is seen after 
530nm.
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hours. Cells were harvested as described in section (2.2.2.3), Protein 
concentrations were determined and 0.5mg protein was resuspended in assay 
buffer for each measurement. Samples were then assayed for HO activity as 
described in section (3.2.) but in this case the reaction was stopped, immediately, 
at 5 minutes, 10 minutes, 15 minutes, or 30 minutes. Using this method it was 
determined that bilirubin production increased linearly for periods of up to 15 
minutes incubation (R2 = 0.9905, n = 3-4). (Figure 3.3). Beyond this point there 
was no further increase in product formation.
HO was induced using hemin in order to measure activity, as the HO assay also 
measures bilirubin produced by any other isoforms of HO it could be expected 
that levels of HO activity due to the constitutive form may be present under basal 
conditions. Table 3.1 shows values for control cells which were treated for 24 
hours before harvest with fresh media only and lOOpM hemin treated cells as 
shown previously in the validation assay.
3.4. Discussion
This chapter has shown a method for measuring HO activity that has been 
validated in primary rat astrocytes. At the time this investigation was started, 
although HO-1 protein had been shown to be expressed in astrocytes, activity 
had not been determined. This is an assay that requires no specialist equipment or 
costly substrates and so has some advantages over other methods. It is important 
however to optimise experimental conditions for the cells/tissue being analysed, 
particularly with regards to time.
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Figure 3.3. HO activity against time
Astrocytes treated with 100pM hemin were assayed using incubation times of up 
to 30 minutes to determine linearity with time. 0.5mg protein assayed, n = 3-4.
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Haem oxygenase activity in rat astrocytes pmol bilirubin/mg/min
Control 21.3 ±5.8
Hemin treated (lOOpM) 61.1 ± 5.3*
Table 3.1. Haem oxygenase activity in rat astrocytes
Rat astrocytes were treated for 24 hours with media alone or lOOpM hemin and 
HO activity measured. Hemin treated astrocytes show a significantly greater 
amount of bilirubin production. Data was mean ± SEM (n = 4 independent cell 
preparations). Statistical significance was determined by students t-test. * p < 
0.05.
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Whilst investigating the spectrophotometric assay for bilirubin production it 
became apparent that there were a number of factors for consideration as 
previously mentioned, the liver cytosol preparation and grade of chloroform in 
particular. A recent paper (McNally et al., 2004) has highlighted other 
considerations in optimising this assay. This group report that, although it is 
possible to measure bilirubin in the aqueous phase, the solubility of bilirubin in 
chloroform is much greater. Bilirubin has a low solubility in phosphate buffer at 
pH 7.4 with a tendency to exist as a colloidal sol or to form large flocculants. The 
true solubility of bilirubin in phosphate buffer has been reported to be less than 
0.1 pM (Lee & Gartner., 1976). However in chloroform the solubility is reported 
to be up to 20mM, although at this concentration it exists as a particulate 
solution. Using a chloroform extraction also reduces the effect that hemin can 
have on the assay. McNally et al, (2004) report that although hemin is required in 
the assay as a substrate, too high a concentration can reduce the sensitivity of the 
bilirubin measurement, but too low a concentration affects the efficiency of the 
enzymatic reaction. A stepwise reduction in apparent bilirubin content with 
increasing hemin concentration above 25 pM in 0.1M phosphate buffer is seen, 
however in chloroform this is not seen until hemin concentrations are above 
50pM. It has also been reported (Tenhunen, 1972) that large amounts of protein 
in the reaction inhibit the function of both haem oxygenase and biliverdin 
reductase. Indeed increasing the amount of biliverdin reductase protein in the 
assay above 6mg did not increase the amount of bilirubin formed (up to 15mg) in 
the reaction and so was used as an optimum amount.
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3.5. Conclusions
The HO method described above has been validated for use in rat astrocytes and 
will be used to determine levels of HO activity under various conditions to 
determine the role of HO activity in NO mediated mitochondrial damage. This 
assay measures all HO activity (HO-1, HO-2 and HO-3) however since HO-2 
is only thought to be responsive to adrenal glucocorticoids (Maines, 1997) and 
HO-3 has only marginal levels of catalytic activity compared to HO-2 
(McCoubrey at al., 1997) increases in HO activity brought about by treatments to 
the astrocytes (other than glucocorticoids) are most likely to be attributable to 
HO-1.
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Chapter 4
The effects of hemin on HO 
induction, GSH status and 
mitochondrial function in 
astrocytes
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4.1. Introduction
In the mature mammalian brain astrocytes constitute nearly half of the total cells 
(Song et al., 2002). In recent years it has become clear that far from being only 
the “glue” that supports the brain structure, astrocytes perform a number of 
crucial functions. Apart from providing structural support for neurons, astrocytes 
are now known to be able to modulate the environment around neurons, release 
neuronal growth factors and help maintain the barrier between blood and brain. 
New roles for astrocytes are still being discovered, for example, in 2002 Song et 
a l, reported that certain astrocytes control neurogenesis. Defense against 
oxidative stress is another important role for astrocytes and it has been shown 
that they are able to protect neurones against oxidative stress via upregulation of 
glutathione synthesis. Glutathione is present at high concentration in the brain 
and acts as a major antioxidant (Meister, 1988, Makar et al., 1994 and Nakamura 
et a l, 1997). It has been suggested that oxidative stress can influence levels of 
GSH by upregulating enzyme activity of glutamate-cysteine ligase (GCL) 
(Iwata-Ichikawa et a l, 1999; Gegg et a l, 2005).
Haem oxygenase (HO) specific activity in the brain exceeds that of various 
organs including the liver (Trakshel et a l, 1986; Maines, 1992); and under 
normal conditions this activity is attributable to HO-2 and is mainly expressed in 
neuronal populations (Ewing & Maines, 1992) and the endothelial lining of the 
blood vessels (Ewing et al ., 1994). However, in response to stress HO-1 is 
expressed at high levels in glial cell populations and macrophages (Ewing & 
Maines, 1991; Ewing et a l, 1992; Ewing & Maines, 1993; Geddes et al., 1996;
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Turner et al., 1998), making it possible that HO-1 induction in glial cells which 
include astrocytes is an important response to stress.
Central nervous system haemorrhage exposes glial cells to high micromolar 
concentrations of haem (Letarte et al., 1993) in the form of haemoglobin, which 
is able to spontaneously, nonenzymatically convert to methaemoglobin (Huang et 
al., 2002), from which hemin readily dissociates (Bunn & Jandl., 1968; Hebbel 
& Eaton., 1989).
Hemin also known as ferriprotoporphyrin IX (Figure 4.1.), differs from haem in 
that the central iron atom in this molecule is in the ferric (Fe3+) state. The 
porphyrin structure is however, the same as haem and it is therefore a substrate 
for the haem oxygenases. Due to the oxidative nature of the hemin molecule it is 
also a very effective inducer of HO-1. At high micromolar concentrations of 
hemin such as may be found in intracranial haematomas, hemin has been found 
to be toxic to various cell types including porcine aortic endothelial cells (Balia 
et al., 1992), myocytes (Bhoite-Soloman et al., 1993), epithiloid sarcoma cells 
(Braverman et al., 1995) and an African green monkey kidney epithelial cell line 
(da Silva et al., 1996). However the mechanisms underlying the toxicity are 
unclear. Hemin accumulates in membranes, and toxic effects may be due to 
interactions with membrane lipids and /or proteins (Shaklai et al., 1985; Leclerc 
et al., 1988). It is also possible that due to hemin’s induction of HO-1 and 
subsequent action of the enzyme, iron could be released from the hemin 
molecule and take part in potentially deleterious oxidative reactions. 
Mechanisms to prevent a toxic overload of iron on the cell are available such as 
ferritin induction which is said to be upregulated in concert with HO-1 induction
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Figure 4.1 Structure of hemin
Adapted from http://www.mpcfacultv. net/
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(Eisenstein et al., 1991) however it is possible that in situations where haem 
overload occurs such as haemorrhage, the ability of ferritin to sequester iron may 
be overwhelmed. Iron release from hemin can also occur via non HO mediated 
methods, since hemin can rapidly react with peroxides resulting in its 
degradation (Kremer, 1989). Increased superoxide production and its conversion 
to H2O2 by superoxide dismutase may increase iron release from hemin via this 
mechanism.
Although there are studies that have shown hemin toxicity at low concentrations, 
not all reports agree with this. Clark et a/.,(2000) show bilirubin mediated 
protection against glucose oxidase (GOX) treatment, an oxidant challenge at 
hemin concentrations up to 200pM in bovine vascular smooth muscle cells 
(Clark et al., 2000). Highest HO activity was seen using lOOpM hemin even 
though highest HO-1 protein expression was seen using 200pM hemin. The 
higher HO activity correlated with an improved protective effect after GOX 
treatment. Other investigations have also shown protective effects of hemin 
mediated HO induction both in vivo and in vitro ( Chen et al., 2004; Hangaishi et 
al., 2000; Le et al., 1999; Aizawa et al., 1999). Hemin has proved to be a useful 
tool to study HO induction, however it must be remembered that enzyme 
induction is not the only effect of this molecule.
In order to study the effects of an enzyme it is also useful to be able to inhibit it. 
Inhibitors of HO have been viewed with increasing interest in recent years, not 
only as a tool to study the enzyme but also as therapeutic agents to prevent 
hyperbilirubinemia in newborns (Kappas, 2004). HO inhibitors are synthetic 
haem analogues with a metal ion other than iron inserted into the centre of the
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porphyrin ring, and inhibit by competitive inhibition. The central metal atom 
does not bind molecular oxygen and this means that it cannot be degraded 
(Drummond & Kappas, 1981). Two of these analogue inhibitors are zinc 
protoporphyrin DC and tin protoporphyrin IX (Figure 4.2 ), which have both 
been used to study the effects of HO inhibition both in vivo and in vitro (Zakhary 
eta l., 1996; Grunemar &Ny, 1997; Doi e ta l, 1999; Cavicchi et al., 2000).
In view of the physiological role that hemin could play in the brain under certain 
conditions and the fact that it is such a potent inducer of HO-1, this molecule was 
used as a model of HO-1 induction in primary rat astrocytes.
The aims of this chapter were to;
1. Examine the effects of hemin treatment on cultured rat astrocytes by 
measuring cell viability, HO-1 expression and HO activity
2. Since it was intended to go on to study the effects of HO induction on 
IFNy/LPS activated astrocytes, the effect of hemin mediated induction of HO 
was also examined on the following parameters which may be affected by 
EFNy/LPS activation; iNOS expression, nitrite/nitrate in cell culture media as an 
index of iNOS activity, cellular GSH levels and mitochondrial respiratory chain 
enzyme activities.
3. Treat cells with ZnPPIX and SnPPIX and assess viability to decide on the 
most suitable inhibitor to use.
4. Treat cells with the most suitable inhibitor and assess amount of HO inhibition 
and investigate what effects this inhibition has on the parameters listed in 1.
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Figure 4.2. Structure of HO inhibitors
Structure of a) tin protoporphyrin IX (SnPPIX) and b) zinc protoporphyrin IX 
(ZnPPIX) (adapted from http ://www. alexi s- corp. com/porphyri n s)
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4.2. Methods
4.2.1. Cell culture
Primary astrocytes were cultured as described in section 2.2 and treated with 
lOOpM hemin, for 3,6,18 and 24 hours. Control cells were treated with medium 
only for the same times. In other experiments cells were treated with 20 pM 
ZnPPIX or SnPPIX for 24 hours.
4.2.2. MTT reduction
Chemical reduction, by cells, of the redox dye MTT was used as an indication of 
cellular redox capacity, which in turn may be interpreted as a measure of cell 
viability (Regan etal., 2002; Goldstein et al., 2003). The tetrazolium salt, 3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide is taken up into cells and 
reduced by a cellular dehydrogenase enzyme to yield a purple formazan product 
which is largely impermeable to cell membranes, thus resulting in its 
accumulation in healthy cells. Solubilisation of the cells results in the liberation 
of this product which can then be detected using a colorimetric assay. 0.12pM 
MTT was made up in HBSS and 1ml of this solution was added to control 
astrocytes and astrocytes treated with lOOpM hemin, 20pM ZnPPIX or 20pM 
SnPPIX for 24 hours.The cells were incubated at 37°C in the dark for 1 hour to 
allow reduction to occur. MTT was reduced to purple formazan crystals, which 
precipitated on the bottom of the well. The supernatant was removed and the 
crystals of formazan were dissolved in 1ml of dimethylsulphoxide (DMSO). The 
absorbance of the samples (using DMSO as a blank) was read at 540nm using a
94
Uvikon 941 spectrophotometer. The absorbance of treated samples was 
expressed as a percentage of absorbance in control samples.
4.2.3. HO assay
Bilirubin production by astrocytes in control, hemin, inhibitor or hemin + 
inhibitor treated cells was determined as described in section 3.2.3,
4.2.4. Spectrophotometric enzyme assays
Complexes I, II+III and IV of the ETC and citrate synthase (CS) were assayed in 
cultured astrocyte homogenates as described in section 2.3
Lactate dehydrogenase release from cultured astrocytes was measured as 
described in section 2.3.5,
4.2.5. Total nitrite/nitrate
Accumulation of the stable breakdown products of NO breakdown nitrite and 
nitrate was measured as described in section 2.4.1, Since the Griess reaction is a 
colourmetric reaction it was necessary to check that hemin or inhibitors used 
during the investigation did not affect results. This was done by making up
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standard concentrations of NaNC>2 and NaNC>3 in media containing hemin or 
inhibitor at the concentration used in the treatment, and then performing the 
assay as usual. Conversion from nitrate to nitrite was also recorded to ensure that 
treatments were not interfering with this process.
4.2.6. GSH quantification
GSH content in cultured astyrocyte homogenates was analysed by reverse-phase 
HPLC as described in section 2.6.
4.2.7. Western blots for HO-1 and iNOS
Expression of HO-1 and iNOS proteins was detemined by subjecting samples to 
SDS-PAGE to separate the proteins then using antibodies to either iNOS and HO 
as described in section 2.5. To show equal loading of protein in each lane an 
actin antibody was also used.
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4.2.8. Protein determination
Sample protein concentration was determined using the Lowry method as 
described in section 2.7.
4.3. Experimental protocols 
Hemin and inhibitor treatments
Hemin , ZnPPIX or SnPPIX were dissolved in a minimal amount of 0.1 M NaOH 
and made up to a stock concentration of 20mM with astrocytic medium, pH was 
checked to ensure that the buffering ability of the media was sufficient to buffer 
this concentration of NaOH, (< 0.1 pH unit difference) . Final treatment 
concentration was lOOpM for hemin, and 20pM for ZnPPIX and SnPPIX in 
astrocytic medium. Control astrocytes were treated with medium alone. 
Astrocytes were treated for 3,6,18, or 24 hours before being harvested for assay.
4.4 Results
4.4.1. Cell viability after hemin or inhibitor treatment
Before assessing the effect of hemin or inhibitors on the various parameters 
chosen it was necessary to establish that the treatment itself would not cause cell
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death. LDH leakage and MTT reduction were used as indicators of cell viability. 
Astrocytes were treated for 24 hours with lOOpM hemin, 20jliM ZnPPIX or 
20pM SnPPlX in media, control cells were treated with media alone. IOOjliM  
hemin treatment or 20 pM SnPPIX treatment for 24 hours did not cause 
significant LDH leakage compared to control (Figure 4.3a) (control, 4% ± 0.4%; 
hemin , 4.75% ± 0.75%: SnPPIX, 3.8% ± 0.25%(n = 4». Hemin or SnPPIX 
treatment also did not significantly affect the astrocytes ability to reduce MTT 
(Figure 4.3b) (control, 100%; hemin, 96.4% ± 2.9%; SnPPIX , 99.5% ± 0.4% (n 
= 4)). ZnPPIX, however affected LDH leakage and MTT reduction in a 
significant manner when measured against controls (Figure 4.3a) (LDH leakage: 
control, 4% ± 0.4%; ZnPPIX, 9.3% ± 0.5% (n = 4) p<0.05) (Figure 4.3b) (MTT 
reduction; control 100%; ZnPPIX, 58.8% ± 10.5% (n = 4) p<0.05).
Since astrocyte viability was significantly affected by ZnPPIX at the 
concentration used SnPPIX was used in all further inhibiton experiments.
4.4.2. Expression of HO-I and iNOS after hemin treatment
Treatment of astrocytes with lOOpM hemin caused enhanced expression of HO-1 
protein at all time points compared to control (Representative blot shown in 
Figure 4.4). Expression was increased by 3 hours of treatment and continued to 
increase up to 24 hours. Control levels of expression did not increase during the 
experiment. iNOS expression was not visible in either the control or treated cells 
although confirmation that the antibody was able to detect this was confirmed by 
the use of a positive control (Figure 4.4). The positive control stimulated with
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Figure 4.3. Measures of astrocyte viability after hemin and inhibitor 
treatment.
Astrocytes were treated with lOOpM hemin, 20pM ZnPPIX, 20pM SnPPIX, or 
media alone (control) for 24 hours. LDH leakage and the ability of cells to 
reduce MTT were then analysed. Hemin or SnPPIX treatment did not 
significantly affect astrocyte viability compared to control as assessed by these 
parameters. ZnPPIX caused a significant decrease in cell ability to reduce MTT 
and a significant increase in LDH leakage against controls. Data are mean ± 
SEM (n = 4). Data was statistically evaluated by one-way ANOVA followed by 
least significant difference test. * p < 0.05.
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iNOS
HO-1
Actin
Figure 4.4. Western blot of HO-1 and iNOS from astrocytes exposed to 
hemin
Astrocytes were treated with media alone (C), or lOOpM hemin (H) for 3,6,18 or 
24 hours. Protein from astrocytes was electrophoresed via SDS-PAGE, 
transferred to a nitrocellulose membrane and probed with antibodies to HO-1 and 
iNOS. Following visualisation the membrane was probed with an anti actin 
antibody to show equal loading of proteins. +C is a positive control for iNOS, a 
murine macrophage cell line, RAW264.7 lysate (LPS and y-interferon 
stimulated).
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IFNy + LPS also showed strong expression of HO-1 protein. Treatment of 
astrocytes with the HO inhibitor SnPPIX also showed a strong expression of HO- 
1 protein, Figure 4.5 shows this expression to be similar to that found when cells 
are treated with hemin + SnPPIX.
4.4.3. HO activity after hemin and HO inhibitor treatment
Bilirubin production as an index of HO activity was measured in astrocytes
grown to confluency in 80cm3 flasks and treated on day 13 with media alone
(control) or media supplemented with lOOpM hemin. Treatments were stopped 
after 3,6,18 and 24 hours. Some flasks were treated with the HO inhibitor 
SnPPIX or a combination of SnPPIX + hemin to investigate the efficacy of the 
inhibitor. Activity in control cells did not change significantly at any time point 
(Figure 4.6a). After 6 hours of hemin treatment enzyme activity 
did become significantly higher than that of controls or 3 hour hemin treated 
cells (hemin treated 6 hours, 110 ± 16.7 pmol/min/mg protein; hemin treated 3 
hours, 25.4 ±1.1 pmol/min/mg protein, p < 0.05, n = 3-5). After 18 hours of 
hemin treatment enzyme activity, although still significantly higher than controls 
was slightly decreased and this trend was continued at the 24 hour timepoint. At 
the 24 hour timepoint enzyme activity was significantly lower than at 6 hours 
(hemin treated 24 hours,71.6 ±11.1 pmol/min/mg protein; hemin treated 6 hours, 
110 ± 16.7 pmol/min/mg protein, p 0.05, n = 3-5) (Figure 4.6a), but still 
remained significantly higher than controls.
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Actin
Control SnPPIX Hemin + 
SnPPIX
Figure 4.5. Western blot of HO-1 protein from cells exposed to an inducer 
and an inhibitor of HO-1
Astrocytes were treated with media alone (control), media supplemented with 
20pM SnPPIX or media supplemented with SnPPIX + IOOjiM hemin. Cells were 
lysed and subjected to SDS-PAGE , transferred to a nitrocellulose membrane and 
probed with antibody to HO-1. The membrane was also probed with an actin 
antibody to show equal loading of protein.
102
a)
c
1c
!5
2
140 
120 « 
100 
8 0- 
6 0- 
40 
20 
0 d
* # 
I
□  Control
□  Hemin
3 hours 6 hours 18 hours 
T reatment time
24 hours
b)
30 i
25*
|  2 0 . 
c
^  15*
k -
Control SnPPIX Hemin + SnPPIX
T reatment
Figure 4.6. Haem oxygenase activity with time and inhibition after hemin 
treatment
Astrocytes were treated with medium alone (control) or medium containing 
lOOpM hemin for 3 to 24 hours (a). Cells were also treated with 20pM SnPPIX 
alone orlOOpm hemin + SnPPIX for 24 hours (b). Haem oxygenase activity in 
these cells was then measured. HO activity was significantly higher in cells 
treated for 6, 18 and 24 hours compared to controls (*), HO activity in cells 
treated with hemin for 6 hours was also significantly higher than activity in cells 
treated for 24 hours (#). Values are mean ± SEM (n = 3-5 independent cell 
preparations). Cells treated with SnPPIX or SnPPIX + hemin for 24 hours 
showed HO activity levels which were not significantly different to controls (n = 
3 -4). Data was statistically evaluated by one-way ANOVA followed by least 
significant difference test, p < 0.05.
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Treatment of astrocytes with SnPPIX for 24 hours did not cause bilirubin 
production to differ significantly from control levels (Figure 4.6b) (control 
24hrs, 21.3 ± 5.8 pmol/min/mg protein; SnPPIX 24hrs, 10.2 ± 3.4 pmol 
bilirubin/min/mg protein, (n = 3)) likewise, the treatment of cells with hemin to 
induce HO-1 activity and an HO inhibitor, SnPPIX showed bilirubin levels 
comparable to control (Figure 4.6b) ( control 24hrs 21.3 ± 5.8 pmol/min/mg 
protein ; SnPPIX + hemin 24hrs 16.6 ± 4.2 pmol/min/mg protein, (n = 3)).
4.4.4. Mitochondrial electron transport chain enzyme activity after hemin or 
HO inhibitor treatment
Given that hemin can act as an oxidant, the activities of the ETC complexes were 
assayed in astrocytes after hemin treatment to determine any effects. Activities 
were also determined after cells had been treated with an HO inhibitor alone or 
together with hemin. Astrocytes seeded onto 6-well plates were treated with 
media alone (control) or media supplemented with lOOpM hemin for 3,6,18 or 
24 hours. Cells were also treated with 20pM SnPPIX alone or SnPPIX + lOOpM 
hemin. Hemin treatment or SnPPIX treatment alone did not result in any 
significant changes in respiratory chain enzyme activity at any time point using 
either protein or citrate synthase as a baseline (Table 4.1). Treating astrocytes 
with SnPPIX + hemin, however caused a significant increase in complex I 
activity against 24 hour control values whether assessed against a protein 
baseline or against citrate synthase (Table 4.2 and Figure 4.7) ( vs protein:
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lours Treatment Comp I 
nmol/min/mg
vs citrate synthase Comp ii/ni 
nmol/min/mg
vs citrate synthase Comp IV 
/t/min/mg
vs citrate synthase 
&/nmol
Cit Synth 
nmol/min/mg
3 Control
Hemin
31.7 ± 3.1 
31.1 ± 2.5
0.203 ± 0.020 
0.222 ± 0.008
14.3 ±0.4  
13.0 ± 1.4
0.091 ±0.003 
0.092 ± 0.007
2.05 ±0.06  
2.09 ±0.03
0.013 ±0.003 
0.015 ±0.001
156.0 ±2.1  
141.6 ± 4.8
6 Control
Hemin
31.9 ±1.1  
36.4 ±2.1
0.221 ±0.018  
0.227 ± 0.005
16.1 ± 1.7
16.1 ±2.3
0.109 ±0.008  
0.090 ±0.011
2.27 ±0.25  
2.40 ±0.24
0.016 ±0.002  
0.018 ±0.001
148.2 ±15.7  
138.6 ±24.4
18 Control
Hemin
34.1 ±0.2  
31.4 ± 5.2
0.256 ±0.028  
0.222 ±0.037
17.1 ±5.3
16.2 ±5.8
0.107 ±0.033  
0.116 ± 0.021
2.26 ±0.13  
2.25 ± 0.13
0.015 ±0.001 
0.016 ±0.001
160.0 ±2.0  
143.7 ± 13.4
24 Control
Hemin
32.2 ± 1.8 
29.0 ± 1.2
0.201 ±0.009  
0.184 ±0.011
15.0 ±2.3  
19.3 ±0.8
0.094 ±0.013  
0.131 ±0.021
2.12 ±0.22  
2.44 ±0.28
0.019 ±0.003 
0.015 ±0.001
160.5 ±9.5  
158.1 ±3.6
Table 4.1 The effect of hemin on the ETC in astrocytes
Astrocytes were treated with medium alone (control) or medium supplemented with lOOpM hemin for 3-24 hours. Following 
treatment cell homogenates were assayed for ETC complex activity. Data were expressed against protein and citrate synthase 
No significant differences were seen in any of the complexes compared to time matched controls after hemin treatment. Data 
are mean ± SEM (n = 3).
Comp I Comp II/III Comp IV Citrate Syn
Treatment nmol/min/mg nmol/min/mg k/min/mg nmol/min/mg
Control 32.2±1.8 15.0*2.3 2.12±0.22 160.5±9.5
SnPPIX 32.6±4.4 11.4±0.8 1.63±0.18 127.0±17.4
Hemin+SnPPIX 75.2+5.1* 15.5±3.2 1.96+0.77 146.9+6.3
Table 4.2.
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Figure 4.7. The effect of inhibiting HO on the ETC
Astrocytes were treated with medium alone (control), 20pM SnPPIX or lOOpM 
hemin plus SnPPIX. Cells were homogenised and ETC enzyme activities 
measured. Activities were expressed against protein, or specific activities 
expressed against citrate synthase which have no units except for complex IV 
(expressed as &/nmol). Hemin + SnPPIX treatment caused a significant increase 
in complex I activity. Values are mean ± SEM (n = 3-5 independent cell 
preparations). Statistical significance was determined by one-way ANOVA 
followed by least significant difference test. * p < 0.05.
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control 24hrs, 32.2 ±1.8 nmol/min/mg protein; SnPPIX+hemin, 75.2 ±5.1 
nmol/min/mg protein, (n = 3) p < 0.01).
4.4.5. GSH levels after hemin treatment
Hemin treatment did not significantly affect GSH levels as compared to control 
at the 3 and 6 hour treatment time. After 18 hours there was a significant increase 
in GSH levels in treated cells (Figure 4.8a) ( control 16.9 ±1.1 nmol/mg protein 
; hemin treated 40.5 ± 6.9 nmol/mg/protein (n = 5-6 independent cell 
preparations) p < 0.01). At 24 hours GSH were still elevated but to a lesser 
extent. Treating cells with SnPPIX alone did not have any significant effects on 
GSH levels compared to control (Figure 4.8b), likewise SnPPIX + hemin did not 
have a significant effect on GSH levels compared to 24 hour controls (Figure 
4.8b).
4.4.6. Nitrite/nitrate levels after hemin treatment
Hemin and SnPPIX were used to prepare a standard curve for the Griess assay as 
described in section 4.2.5, The standard curve showing conversion of nitrate to 
nitrite is shown in Figure 4.9, and shows conversion of nitrate to nitrite when 
media was supplemented with lOOpM hemin (Figure 4.9a) and when media was 
supplemented with 20pM SnPPIX Conversion of nitrate to nitrite was not 
affected by the presence of lOOpM hemin or 20pM SnPPIX. The comparison of
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Figure 4.8. GSH levels in astrocytes treated with hemin over time and an 
HO inhibitor
Astrocytes were treated with media alone (control) or media containing lOOjiM 
hemin for 3 to 24 hours. Cells were also treated with 20gM SnPPIX alone or 
20gM SnPPIX + lOOgM hemin for 24 hours. GSH levels in cell homogenates 
were then measured. GSH levels in cells treated with lOOjiM hemin for 18 hours 
were significantly higher than levels at any other control point, or levels after 3 
and 6 hours of hemin treatment. Values are mean ± SEM (n = 4 -6 independent 
cell preparations). Data was statistically evaluated by one-way ANOVA followed 
by least significant difference test. * p < 0.05.
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Figure 4.9. Greiss assay standard curve using media supplemeted with 
hemin and SnPPIX
The representative nitrite standard curves show the absorbance of both nitrite 
standards (♦) and the reduced nitrate standards (■) following reduction with 
nitrate reductase. In figure a) standards are made up in media supplemented with 
20pM SnPPIX , in figure b) standards are made up with media supplemented 
with lOOpM hemin.
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the media alone standard curve, the media plus hemin and the media plus 
SnPPIX standard curve for nitrite is shown in Figure 4.10. This indicates that 
when lOOpM hemin or 20pM SnPPIX was included in the media used to make 
up the standard curve for nitrite absorbance, values obtained were no different 
than when just media was used alone. Although the hemin and SnPPIX are 
coloured and do indeed cause a higher absorbance reading, once the zero 
concentration absorbance reading has been subtracted from all readings this 
standardised the curve.
Astrocytes were treated with lOOpM hemin for 3,6,18 and 24 hours. Control 
astrocytes in 6-well plates were treated with media alone for the specified times. 
Astrocytes were also treated with 20pM SnPPIX alone or lOOpM hemin plus 
20pM SnPPIX. At the end of the treatment time the media was removed and 
assayed for nitrite via the Griess reaction after any nitrate had been converted to 
nitrite by nitrate reductase. Results were expressed against protein per well. 
Incubation with hemin for 3,6,18 and 24 hours did not have a significant effect 
on nitrate/nitrite levels in astrocytes as compared to controls (Figure 4.11.).
4.5. Discussion
In the astrocyte cell culture system used here, treatment of astrocytes with 
lOOpM hemin did not cause significant cell death as assessed by LDH release 
which would indicate disrupted cell membranes and MTT assay which gives an 
indication of the redox capability of the cell. These are both assays routinely used
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Figure 4.10. Comparison of nitrite standard curves
The standard curves shown are for nitrite in media alone (♦) nitrite in media + 
hemin (■) and nitrite in media + SnPPIX ( ).
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Figure 4.11. Nitrite/nitrate levels in media after astrocytes were treated 
with hemin over time and an HO inhibitor
Astrocytes were treated with medium only (control) or with lOOpM hemin for 3 
-  24 hours. Cells were also treated with 20pM SnPPIX alone or 20pM SnPPIX + 
lOOpM hemin for 24 hours. Accumulated nitrite levels in the medium were 
measured. Hemin treatments for periods of up to 24 hours did not significantly 
effect nitrite levels as compared to controls. Treating with SnPPIX alone or 
hemin + SnPPIX also had no significant effect on nitrite production compared to 
24 hour control. Data are mean ± SEM (n = 4 -6). Statistical analysis was by one­
way ANOVA followed by least significant difference test.
112
to evaluate cell viability (Goldstein et ah, 2003;Regan et al.,2002; Koh & Choi, 
1988) The decision to use lOOpM hemin was after Clark et ah, (2000), with the 
intention of upregulating HO-1 activity as much as possible whilst maintaining 
cell viability. In their paper, Clark et al., used concentrations of hemin up to 
200pM to treat vascular smooth muscle cells in order to upregulate the activity of 
H0-1 and investigate cellular protection by bilirubin. It was discovered that the 
highest enzyme activity and hence amount of bilirubin production was achieved 
with a concentration of lOOpM. At the 200pM concentration, activity was 
diminished and expression of inducible heat-shock protein 70 (hsp70) was 
stimulated, suggesting hemin toxicity.
The HO inhibitors tested gave very different results, SnPPIX did not affect cell 
viability by either LDH release or the ability of the cell to reduce MTT, but 
ZnPPIX caused a two-fold increase in LDH leakage and a 40% decrease in the 
redox capability of the cells. Similar cytotoxicity has been reported previously 
(Lutton et ah, 1997, Jozkowicz & Dulak, 2003), however this may be cell type 
dependent (Jozkowicz & Dulak, 2003). The central atom in haem analogues does 
appear to affect the biological properties of metalloporphyrins. Tin when 
incorporated into the porphyrin ring structure is extremely stable and there is at 
present no known physiological method by which it can be removed from the 
complex (Jozkowicz & Dulak 2003). Zinc porphyrins however are highly labile 
(Lutton et ah, 1997) and it has been postulated that their cytotoxicity may be due 
in part to the release of the zinc atom from the porphyrin ring, as zinc is able to 
substantially alter normal cell functions, leading to inhibition of iNOS activity 
(Sakaguchi et ah, 2002) and increasing cell death rate (Koh et ah, 1996; Lutton 
eta l., 1997; Kim etal., 1999).
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It has previously been reported that hemin is toxic to cells in culture at low 
concentrations (Balia et al., 1992; Bhoite-Solomon et al., 1993; Braverman et al.,
1995) however different cell types may have differing resistance to oxidative 
stress, and different levels of endogenous antioxidants.. Chen & Regan., (2004) 
show considerable toxicity to mouse cortical astrocytes using 30-60pM hemin, 
however in their investigation cells were treated in media which contained no 
serum. In the current investigation 10% FCS was used in all treatment media. It 
may be that when serum is used in the treatment medium the hemin is able to 
bind with a /some serum components and is prevented from accumulating in cell 
membranes (Shaklai, 1985) and causing lipid peroxidation . It has been shown 
that hemin is a very effective catalyst of lipid peroxidation chain reactions (Van 
den Berg et al., 1988).
HO-1 expression in control astrocytes was detectable but not enhanced at any 
time during the 24 hours of incubation. This is in agreement with reports that 
under normal unstressed conditions the main isoform of HO expressed in the 
brain is HO-2 (Ewing & Maines, 1992). Hemin treatment for 3 hours results in a 
prominent increase in HO-1 protein and protein levels remained increased for the 
duration of treatment. Induction of expression agrees with previous reports, Clark 
et al., (2000) and Maruhashi et al., (2004) find increased HO-1 protein 
expression after 2 hours of hemin treatment in smooth vascular cells and 
ECV304 cells respectively. Clark et al., (2000) see a maximal induction at 4 
hours expression, at 16 hours this expression was reduced. This was not the case 
in this thesis, where expression continued to increase up to the 24 hour 
timepoint, however the experimental protocol was different in that this group
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(Clark et al., 2000) incubated cells with hemin for only 2 hours followed by 
incubation with medium alone. Their results suggest an initial response to hemin 
followed by a return to basal conditions, since the cells in the present study were 
exposed to hemin throughout the treatment time we could expect the results to be 
different. Similarly Maruhashi et al., (2004) saw maximal expression at 8 hours 
but then a reduced expression at 24, this may reflect different cell type or culture 
conditions. SnPPIX caused an increased expression of HO-1 protein either alone 
or when used in conjunction with hemin, and at first thought this may seem 
suprising, but it has been found that although SnPPIX is a potent inhibitor of HO 
activity it is also an inducer of HO-1 protein. Eisenstein etal., (1991) found that 
administration of SnPPIX to rats resulted in a 17-fold induction of HO-1 protein 
in liver although HO activity actually decreased by >90%.
Expression of iNOS protein was also investigated, since after hemin treatment 
astrocytes take on a more stellate, apparently activated morphology and iNOS 
expression is found when cells are activated (Loihl et al., 1999). Neither control 
nor hemin treated cells showed iNOS expression, a positive control, murine 
macrophage cell line, (RAW264.7 lysate stimulated with LPS and y-interferon) 
confirmed that the antibody was detecting iNOS protein, interestingly a strong 
HO-1 band was also detected in this lysate. Not surprisingly the measurement of 
nitrite in culture media after culture treatment showed no significant difference 
from controls. It does appear that nitrite/nitrate levels do rise during the treatment 
period, however this is not a significant rise either when results are evaluated as 
time matched controls or as a single group.
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Activity of HO, which is the combined activity of all HO isoforms, is 
significantly enhanced in astrocytes after 6 hours of hemin treatment compared 
to controls, this is also when activity is maximal, and although activity is still 
significantly higher than that of controls at 18 and 24 hours it is significantly 
lower at 24 hours than at 6. This peak in activity at around 6 hours and 
subsequent decline in activity is in agreement with previous investigations. A 
significant increase in HO activity has been found in human macrophages and 
human glioma cells after a 5 hour incubation with hemin (Yoshida et al., 1988), a 
similar increase was seen in pig alveolar macrophages with a peak at 5-7 hours 
and then a gradual decline thereafter (Shibahara et al., 1978). A maximal activity 
at 6 hours and decline thereafter was also recorded in skeletal muscle cells 
(Vesely et al., 1998). The HO assay is a measure of the HO activity present 
within the cell at a particular time, the reason that the activity actually decreases 
with a longer treatment time may be that as well as being an inducer of the 
enzyme hemin can also inhibit the enzyme. There is some evidence for this in 
skeletal muscle cells, where Vesely et al., (1998) found that although HO 
activity declined with increasing hemin concentration there were no decreases in 
protein or mRNA levels indicating that loss of activity was not due to 
downregulation of gene expression . In this study the fact that protein expression 
was still elevated at 24 hours suggests that this could be an enzyme function 
effect rather than a downregulation of protein synthesis. Administration of 
SnPPIX as mentioned before caused an increased expression of HO-1 protein, 
however an increase in HO activity did not follow with levels lower than control. 
The hemin mediated induction of HO activity was completely abolished when 
hemin was used in conjuction with SnPPIX suggesting that this haem analogue
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is effective as an inhibitor of HO activity, indeed it has been reported that 
SnPPIX has a binding affinity for the enzyme greatly exceeding that of the 
natural substrate (Drummond & Kappas, 1981).
Measurement of respiratory chain enzyme activities showed no significant 
differences in hemin treated cells as compared to controls at any treatment time. 
This was true when activities were expressed against a protein baseline or 
against citrate synthase activity. Complex activites can be expressed against 
citrate synthase to allow for differences in mitochondrial enrichment between 
cell cultures (Selak et al., 2000). As discussed previously hemin has been shown 
to be an oxidant (Shaklai et al., 1985; Leclerc et al., 1988) and it might have 
been expected that hemin treatment would have a detrimental effect on electron 
transport activities, however HO-1 induction and activity shown to be 
significantly raised at the 6 hour treatment timepoint would mean that bilirubin 
would be present in the cell and could act as an antioxidant. As well as bilirubin, 
cellular levels of reduced glutathione (GSH) may be protective, and the cell GSH 
concentration has been implicated in protecting the enzymes of the electron 
transport chain from oxidative stress (Bolanos et al., 1995,1996; Barker et al.,
1996). Using hemin and SnPPIX however caused a significant increase in 
complex I activity, this may be due to oxidative stress caused by hemin 
treatment. It has been previously shown that despite the fact that oxidative stress 
has been shown to inhibit ETC enzymes, complex I activity can actually be 
raised in response to a mild oxidative stress (Ceaser et al., 2003; Vasquez et al., 
2001). This could have effects downstream, and eventually cause inhibition of 
enzymes due to overproduction of electrons from complex I overwhelming the
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other complexes. When astrocytes are treated with hemin alone, HO activity is 
stimulated and bilirubin is able to exert its antioxidant effects, however when HO 
activity is inhibited there will be minimal bilirubin present and a rise in complex 
I could conceivably occur.
Studies have shown that glutathione levels and HO-1 expression appear to be 
linked as a concerted stress response in the cell. Depletion of GSH causes an 
upregulation of HO-1 protein (Ewing & Maines, 1993; Oguro et al., 1996; Ryter 
& Choi 2005) and addition of GSH or its precursors causes a decrease in HO-1 
expression and activity (Foresti et al., 1997). It has been reported that in 
mammals, after liver and kidney, the highest levels of GSH are found in the brain 
(Thompson et al., 1999; Liu & Choi, 2000; Liu, 2002). Within the brain there are 
variations in GSH levels from region to region (Kang et al., 1999; Liu, 2002) and 
also between cell types (Sagara et al., 1993; Makar et al., 1994; Bolanos et al.,
1995). For example cortical astrocyes cultured alone as used in this study, have 
higher GSH levels than neurones from the the same region (Raps et al., 1989; 
Bolanos et al., 1995).
In the present study GSH levels were significantly raised at 18 hours of 
treatment, this is when HO-1 activity has started to decrease and may be a 
response to hemin mediated oxidative stress. It has been shown that oxidants can 
increase expression of the first enzyme in the GSH synthesis pathway, glutamate- 
cysteine ligase. (Tian etal., 1997; Moellering et al., 1998; Iwata-Ichikawa et al., 
1999; Gegg et al., 2005). It may be that whilst HO-1 activity is maximal bilirubin 
production is sufficient to deal with the oxidant challenge caused by hemin 
treatment, and this is why respiratory chain enzyme activity is preserved. Once
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HO-1 activity starts to decline it is possible that GSH production is stimulated to 
take over this role. If this is the case then you would expect to see an increase in 
GSH levels when HO activity is inhibited, however after 24 hours of exposure to 
hemin and SnPPIX GSH levels in astrocytes are not significantly raised 
compared to 24 hour controls. The reasons for this are not clear, though it is 
possible that induction of HO-1 protein alone is preventing this rise in this 
situation. Kaizu et a l , (2003) report that preconditioning with SnPPIX induces 
HO-1 protein but attenuates ischemia/reperfusion injury in the rat kidney, 
independently of HO enzyme activation.
4.6. Conclusions
Hemin treatment induces both HO-1 protein and enzyme activity in astrocytes. 
The reason for maximal enzyme activity 6 hours after treatment is not clear, but 
is in agreement with other studies (Shibahara et al., 1978; Yoshida et al., 1988; 
Vesely et al., 1998). Importantly levels of HO activity are still significantly 
raised 24 hours after hemin treatment Although hemin can cause toxicity (Balia 
et al., 1992; Bhoite-Soloman et al., 1993; Braverman et al., 1995; da Silva et al.,
1996), at the concentration used in this investigation and in the cell type used this 
is not evident. This may be due to the increase in HO activity causing bilirubin to 
be present, since it has been reported that bilirubin is the most abundant 
endogenous antioxidant in mammalian tissues and accounts for the majority of 
antioxidant activity in human serum (Gopinathan et a l, 1994). Normal GSH 
levels in astrocytes may also be protective here as GSH is a major antioxidant in 
the brain (Meister, 1988; Makar et a l, 1994; Nakamura et a l, 1997). The rise in
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GSH levels at 18 hours following a decrease in HO activity does suggest a 
synchronisation of antioxidant defenses maintaining the status quo within the 
cell.
Hemin does not activate or induce iNOS protein or deleteriously affect 
respiratory enzyme chain activites making it a suitable HO-1 inducer to use 
whilst manipulating the NO status of the cell which will be the focus of the next 
chapter. SnPPIX has proven to be an effective inhibitor of HO activity and does 
not affect cell viability, making it a useful tool to study further HO-1 induction. 
However it does appear to have an effect on complex I when used in conjunction 
with hemin which may be caused by the absence of the antioxidant bilirubin due 
to HO activity being inhibited. It is possible that other anti-oxidants are being 
depleted also and whilst it has been shown that depletion of glutathione 
upregulates complex I activity in rat astrocytes and C6 glioma cells (Vasquez et 
al., 2001) it could be possible that this is true for other protective molecules. 
SnPPIX alone does not appear to affect any of the parameters measured in this 
study apart from an upregulation of HO protein which has been documented 
previously (Sardana & Kappas, 1987).
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Chapter 5
HO/iNOS interactions in 
astrocytes; effects on GSH status 
and mitochondrial function
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5.1. Introduction
Production of NO by inducible nitric oxide synthase (iNOS) has been associated 
with perturbed mitochondrial function in a number of neurodegenerative 
disorders (for review see Stewart & Heales 2003). It has also been shown that 
NO and NO related species can markedly increase expression of HO-1 
(Motterlini et al., 1996, Foresti et al., 1997, Forresti & Motterlini, 1999, 
Motterlini et al., 2000). Indeed increased HO-1 expression is reported to be 
upregulated in many diseases including those that cause neurodegeneration 
(Schipper, 2004).
Nitric oxide (NO) is a small diffusible highly reactive molecule. It is synthesised 
in mammals by the nitric oxide synthases (Kwon et al., 1990; Leone et al., 
1991). There are generally accepted to be three isoforms of NOS, NOS I (nNOS), 
NOS n  (iNOS), and NOS III (eNOS). NOS isoforms I and II are Ca2+ dependent 
and constitutive, whereas NOS II is Ca independent and inducible. Numerous 
roles for NO have been identified, for example, neurotransmitter release, 
morphogenesis, synaptic plasticity and regulation of gene expression (Dawson & 
Dawson 1996). However as mentioned above inappropriate formation of NO is 
now thought to be an important source of toxicity in many neurodegenerative 
disorders. In glial cells such as astrocytes this toxicity can occur via activation of 
iNOS, the inducible NOS isoform.
Bolanos et al., (1994) showed that treatment of primary astrocytes with 
lipopolysaccaride (LPS) + interferon gamma (IFNy) for 18 hours caused a 25%
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irreversible inhibition of cytochrome c oxidase activity (complex IV of the 
mitochondrial respiratory chain) compared to untreated controls. After 36 hours 
this inhibition had risen to 56% and succinate-cytochrome c reductase activity 
(Complex II-ffl) was inhibited by 35% compared to untreated controls. This 
inhibition could be prevented by the presence of NG-mono-methyl-L-arginine, 
an iNOS inhibitor.
As already shown in the previous chapter hemin can be used to upregulate HO-1 
expression and HO activity in astrocytes, thus a combination of hemin and 
IFNy/LPS treatment with the appropriate inhibitors could be used to study 
HO/iNOS interaction within the cell.
Aims
Given that HO-1 expression is known to be enhanced by activation of astrocytes 
with IFNy/LPS (Motterlini et al., 1996; Foresti et al., 1997; Foresti & Motterlini, 
1999; Motterlini et al., 2000), the aims of this chapter are to examine the effects 
of IFNy/LPS mediated iNOS activation on HO activity, and whether 
manipulation of the HO status of the cell can affect mitochondrial respiratory 
chain activities, GSH status and nitrite production after IFNy/LPS treatment. In 
addition an exogenous source of NO, (Z)-l-[2-(2-aminoethyl)-N-(2- 
ammonioethyl)amino]diazen-l-iuml,2diolate (DETA-NO) will be used to 
examine the differences between an endogenous source of NO involving 
activation of iNOS , and an exogenous source of NO, which does not involve the
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iNOS pathway, on HO-1 expression and activity, ETC enzyme activities, 
nitrite/nitrate production and GSH status.
5.2. Methods
5.2.1. Cell culture
Primary rat astrocytes were cultured as described in section 2.2. and treated as 
described in the experimental protocols section. All treatments were for 24 hours.
5.2.2. HO assay
Bilirubin production by astrocytes in control and treated cells was determined as 
described in section 3.2.3. and used as an indication of HO activity.
5.2.3. Spectrophotometric enzyme assays
Complexes I, II+III and IV of the ETC and citrate synthase (CS) were assayed in 
control and treated astrocyte homogenates as described in section 2.3.
5.2.4. Total nitrite/nitrate assay
Accumulation of the stable breakdown products of NO breakdown nitrite and 
nitrate was measured in media from control and treated astrocytes as described in
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section 2.4.1. by the Griess assay. Nitrate was first reduced to nitrite using nitrate 
reductase.
5.2.5. GSH quantification
GSH content of control and treated astrocytes was analysed by reverse-phase 
HPLC as described in section 2.6
5.2.6. Western blots for HO-1
Expression of HO-1 and iNOS proteins in control and treated astrocytes was 
determined by subjecting samples to SDS-PAGE to separate the proteins, then 
transferring the proteins to a nitrocellulose membrane and using antibodies to 
HO-1 as described in section 2.5. To confirm equal loading of protein in each 
lane an actin antibody was used.
5.2.7. Protein determination
Sample protein concentration was determined using the Lowry method as 
described in section 2.7.
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5.3. Experimental Protocols
Hemin and SnPPIX treatments
Hemin or SnPPIX were dissolved in a minimal amount of 0.1M NaOH and made 
up to a stock concentration of 20mM with astrocytic medium, pH was checked to 
ensure the buffering ability of the media was sufficient to buffer this 
concentration of NaOH (<0.1 pH unit difference). All treatments were for 24 
hours.
IFNy/LPS treatments
IFNy was made up to a stock concentration in sterile HBSS/0.1% BSA. 
Treatment was lOOU/ml. LPS was made up to a stock concentration in sterile 
HBSS and treatment was lpg/ml.
Depletion of GSH
Astrocytes were treated with media supplemented with 0.5mM L-buthionine- 
S,R-sulfoximine (L-BSO), an inhibitor of glutamate-cysteine ligase (GCL) 
(Meister, 1991) for 24 hours in 6-well plates. Media was removed, cells washed 
twice with HBSS and media containing appropriate treatment replaced for a 
further 24 hours.
DETA-NO treatments
DETA-NO was dissolved in astrocytic media and treatments were 0.5mM. . In 
control experiments, media was supplemented with the same concentration of 
degraded DETA-NO. This had been previously incubated at 37°C for 7 days. 
None of the treatments significantly increased LDH release compared to controls
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5.4. Results
5.4.1. Nitrite/nitrate accumulation in media after IFNy/LPS treatment.
Astrocytes were seeded onto 6 well plates and treated with media alone (control), 
media supplemented with lOOU/ml EFNy ± lpg/ml LPS which have been shown 
previously to activate iNOS and with it NO production (Bolanos et al 1994; 
Brown et a l, 1995) or media supplemented with IFNy/ LPS + 0.5mM L-NIL a 
specific inhibitor of iNOS (Bryk & Wolff), for 24 hours. Media was removed 
and nitrite levels were determined after nitrate conversion to nitrite as described 
in section 2.4.1, Treatment with IFNy/LPS caused a significant, more than two­
fold increase in nitrite accumulation (Figure 5.1) (control, 30.8 ± 9.7 nmol 
nitrite/mg protein; IFNy/LPS, 76.4 ±10.5 nmol nitrite/mg protein). If L-NIL was 
used with IFNy/LPS the rise in nitrite accumulation was abolished (Figure 5.1).
5.4.2. ETC activity after IFNy/LPS treatment
Astrocytes were seeded onto 6 well plates and treated with media alone (control), 
media supplemented with lOOU/ml IFNy + lpg/ml LPS or media supplemented 
with 0.5mM L-NIL a specific inhibitor of iNOS, for 24 hours. ETC complex 
activities were then measured in cell homogenates. Complex I activity was 
significantly higher in IFNy/LPS treated cells than control when assessed against 
citrate synthase activity (Figure 5.2) (vs CS: control, 0.20 ± 0.01; IFNy/LPS, 
0.35 ± 0.01, (n = 3-6) p < 0.05).This was not the case when activity was assessed 
against protein however a high SEM in this set of results may well be the reason 
for this. Complex IV activity in cells treated with IFNy/LPS was significantly
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Figure 5.1. Nitrite/nitrate accumulation in media after IFNy/LPS treatment
Astrocytes were treated with media alone (control), media supplemented with 
lOOUml EFNy/ lpg/ml LPS or supplemented with IFNy/LPS + 0.5mM L-NIL, 
for 24 hours. Accumulation of nitrite in media of cells treated with IFNy/LPS 
was significantly increased compared to controls. Use of the iNOS inhibitor L- 
NIL resulted in levels of nitrite accumulation not significantly different to 
controls. Data is mean ± SEM. Data was statistically evaluated by one-way 
ANOVA followed by LSD. *p < 0.05.
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Treatment Comp I 
nmol/min/mg
Comp I I/I 11 
nmol/min/mg
Comp IV 
Ar/min/mg
Citrate Synth, 
nmol/min/mg
Control 32.2 ± 1.8 15.0 + 2.3 2.12 + 0.22 160.5 + 9.5
IFNy/LPS 54.9+ 10 10.7+1.4 0.55 + 0.18* 141.0 + 21.8
IFNy/LPS+L-NIL 48.2 + 6.9 11.5 + 2.7 1.62 + 0.19 163.1 +22.5
Table 5.1.
0.025
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0.02
0.3-
0.015 -o
Ec20.2  <
0.1 < 0.005 •
IFNy/LPS IFNy/LPS+L-NIL IFNy/LPS IFNy/LPS+L-NILControl Control
□ Com plex I a Com plex ll/lll □ Com plex IV
Figure 5.2. Effect of IFNy/LPS treatment on the ETC
Astrocytes were treated with medium alone (control), medium supplemented 
with lOOU/ml IFNy + lpg/ml LPS or medium supplemented with IFNy/LPS + 
0.5mM L-NIL. Following 24 hours of treatment cell homogenates were assayed 
for ETC complex activity. Data were expressed against protein and citrate 
synthase. IFNy/LPS treatment caused a significant rise in complex I activity 
against control when measured against a citrate synthase baseline and a 
significant decrease in complex IV activity when measured against protein or 
citrate synthase . Data are mean ± SEM (n = 3-6) Data was statistically evaluated 
by one-way ANOVA followed by least significant difference test * p < 0.05.
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lower than controls whether assessed against a protein baseline or against citrate 
synthase activity (Figure 5.2) (vs protein: control, 2.12.± 0.22 nmol/min/mg 
protein; IFNy/LPS, 0.55 ± 0.18 nmol/min/mg protein, (n = 3-6) p < 0.05). 
Stimulating astrocytes with IFNy/LPS whilst using the iNOS inhibitor L-NIL 
gave ETC complex activites which were not significantly different to controls.
5.4.3. HO expression and activity after IFNy/LPS treatment
Treatment of astrocytes with IFNy/LPS causes enhanced expression of HO-1 
protein which greater compared to expression in control cells (Figure 5.3a) , 
expression is still enhanced when astrocytes are treated with the iNOS inhibitor 
L-NIL, or the HO inhibitor SnPPIX (Figure 5.3a). IFNy/LPS treatment caused a 
significant, approximately 2-fold increase in HO activity as compared to control 
activity (Figure 5.3b) (Control 21.3 ± 5.8 pmol bilirubin/min/mg protein; 
IFNy/LPS 50.3 ± 3 .6  pmol bilirubin/min/mg protein (n = 3-4 independent cell 
preparations) p < 0.05). However treatment of astrocytes with IFNy/LPS and L- 
NIL or SnPPIX resulted in HO activity comparable to control levels despite 
raised expression.(Figure 5.3b).
5.4.4. ETC activities after IFNy/LPS treatment and induction or inhibition 
of HO-I.
As previously mentioned treatment of astrocytes with IFNy/LPS caused complex 
I to be significantly higher than control (assessed against a citrate synthase 
baseline) and complex IV to be significantly lower (assessed against protein or
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Figure 5. 3. The effects of IFNy/LPS treatment on HO expression and 
activity
Flasks of astrocytes were treated with media alone (control), 1 OOU/ml IFNy/ 
lpg/ml LPS with either 0.5mM L-NIL or 20pM SnPPIX. All treatments raised 
HO-1 protein expression against control. IFNy/LPS treatment raised HO activity 
significantly vs control. Using an iNOS inhibitor (L-NIL) or an HO inhibitor 
with IFNy/LPS brought activity back to control levels. Data are expressed mean 
± SEM (n = 3-4). Data was statistically evaluated by one-way ANOVA followed 
by least significant difference test. *p < 0.05.
131
citrate synthase). Treatment with IFNy/LPS + SnPPIX, the HO inhibitor, caused 
the activity of complex IV to be significantly decreased compared to control 
(Table 5.2 and Figure 5.4) (vs protein: control , 2.12 ± 0.22 ^/min/mg protein; 
IFNy/LPS ± SnPPIX, 1.0 ± 0.2 £/min/mg protein (n = 3 -5 independent cell 
preparations) p < 0.05). Treatment of astrocytes with IFNy/LPS + hemin caused 
a significant rise in complex I activity when assessed against citrate synthase 
(Figure 5.4) (vs CS: control, 0.201± 0.01; IFNy/LPS + hemin, 0.336 ± 0.07 (n = 
3-5 independent cell preparations) p < 0.05). All other ETC complex activities 
including complex IV where treated with IFNy/LPS + hemin , were not 
significantly different to controls.
5.4.5. Effect of inhibiting or inducing HO on HO activity and expression of 
HO-1 in IFNy/LPS treated astrocytes
As discussed previously, treating astrocytes with IFNy/LPS caused both 
enhanced expression of HO-1 protein and elevated HO activity. If astrocytes 
were treated with IFNy/LPS and hemin, expression appeared to be greater than 
treatment with IFNy/LPS alone (Figure 5.5a) and activity was significantly 
greater than control and IFNy/LPS treated cells (Figure 5.5b) (control, 21.3 ± 5.8 
pmol bilirubin/min/mg protein; IFNy/LPS, 50.3 ± 3 .6  pmol bilirubin/min/mg 
protein; IFNy/LPS ± hemin, 88.1 ± 7.1 pmol bilirubin/min/mg protein (n = 3-4 
independent cell culture preparations) p <0.05).
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Treatment Comp I 
nmol/min/mg
Comp II/III 
nmol/min/mg
Comp IV 
k/min/mg
Citrate synth. 
nmol/min/mg
Control 32.2+1.8 15.0 + 2.3 2.12 + 0.22 160.5 + 9.5
IFNy/LPS+SnPPIX 46.7 + 8.2 17.4 + 2.5 1.0 ±0.2* 199.7 + 31.8
IFNy/LPS+hemin 48.8 + 9.7 15.1+2.1 2.14 + 0.45 151.5 + 22.7 i
Table 5.2
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Figure 5.4. ETC enzyme activities after treatment with IFNy/LPS and an 
inducer or inhibitor of HO
Astrocytes were treated with media alone (control) or media supplemented with 
lOOU/ml IFNy/ lpg/ml LPS + 20pM SnPPIX or IFNy/LPS + lOOpM hemin for 
24 hours. Cell homogenates were assayed for ETC complex activity. Data were 
expressed against a protein baseline and citrate synthase activity. Treatment with 
IFNy/LPS+hemin caused a significant rise in complex I activity against control 
when expressed against citrate synthase. A significant decrease in complex IV 
activity was seen when cells were treated with IFNy/LPS+SnPPIX whether 
expressed against protein or citrate synthase. Data are mean ± SEM (n = 3-5 
independent cell preparations). Statistical evaluation was by one-way ANOVA 
followed by least significant difference test. * p < 0.05.
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Figure 5.5. Expression and activity of HO when astrocytes are treated with 
IFNy/LPS and inducers or inhibitors of HO-1
Astrocytes were treated with media alone (control) lOOU/ml IFNy/ 1 pg/ml LPS, 
IFNy/LPS + lOOpM hemin or IFNy/LPS + 20^M SnPPIX for 24 hours. Western 
blotting using an antibody to HO-1 (a) shows increased expression when cells are 
treated with IFNy/LPS as compared to control, and expression is more enhanced 
when hemin is added to IFNy/LPS. Activity of HO is raised significantly against 
control when astrocytes are treated with IFNy/LPS (b) and significantly against 
control and IFNy/LPS treated cells when hemin is added to IFNy/LPS. HO 
activity data is mean ± SEM (n = 3-4 independent cell preparations). Statistical 
evaluation was by one-way ANOVA followed by least significant difference 
test. * p < 0.05, ** p <0.01, fp<0.05 against IFNy/LPS treated cells.
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5.4.6. Effect of inhibiting or inducing HO on nitrite/nitrate levels in media 
from astrocytes treated with IFNy/LPS
Treatment of astrocytes with IFNy/LPS causes iNOS to be activated and NO to 
be released by the cell, this significant NO production has been shown previously 
(Figure 5.1.). Adding hemin to IFNy/LPS causes a significant increase in nitrite 
accumulation in media, (Figure 5.6) (control, 30.8 ± 9.7 nmol nitrite/mg protein; 
IFNy/LPS + hemin 68.6 ±10.1 nmol nitrite/mg protein (n = 3 -5 independent cell 
preparations) p < 0.05). Adding SnPPIX however to IFNy/LPS causes nitrite 
accumulation in media to be even more significantly higher than control (Figure 
5.6) (control, 30.8 ± 9.7 nmol nitrite/mg protein; IFNy/LPS + SnPPIX, 100.9 ± 
21.9 nmol nitrite/mg protein (n = 3-5 independent cell preparations) p < 0. 01).
5.4.7. Effect of induction or inhibition of HO on GSH levels in astrocytes 
treated with IFNy/LPS
Astrocytes treated with IFNy/LPS + hemin showed significantly higer levels of 
glutathione than control cells or those treated with IFNy/LPS alone (Figure 5.7) 
(control, 21.4 ± 3.6 nmol/mg protein: IFNy/LPS, 19.2 ± 3 nmol/mg protein, 
IFNy/LPS + hemin 50.8 ± 8.6 nmol/mg protein (n = 4 -  6 independent cell 
preparations) p < 0.05). Treatment with the HO inhibitor SnPPIX and IFNy/LPS 
did not cause glutathione levels to change significantly.
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Figure 5.6. Nitrite/nitrate levels in media after treatment of astrocytes with 
IFNy/LPS with an inducer or an inhibitor of HO-1.
Astrocytes were treated with media only (control) or with lOOU/ml IFNy/1 pg/ml 
LPS + lOOpM hemin or IFNy/LPS + 20pM SnPPIX for 24 hours. Media was 
removed and nitrite levels were measured after nitrate was converted to nitrite as 
previously described. Treatment with IFNy/LPS + hemin and IFNy/LPS + 
SnPPIX caused nitrite levels to rise significantly compared to control. Data are 
mean ± SEM (n = 3-7 independent cell preparations). Statistical evaluation was 
by one-way ANOVA followed by least significant difference test * p < 0.05 ** p 
< 0 .01 .
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Figure 5.7. GSH levels in astrocytes treated with IFNy/LPS and an inducer 
or inhibitor of HO.
Astrocytes were treated with media alone (control) or media supplemented with 
lOOU/ml IFNy/lpg/ml LPS + 20pM SnPPIX or IFNy/LPS + lOOpM hemin for 
24 hours after which time cellular GSH levels were determined. Treatment with 
IFNy/LPS + hemin caused levels to rise significantly compared to control. Other 
treatments had no significant effect. Data are mean ± SEM (n = 4-6 independent
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cell preparations). Statistical evaluation was by one-way ANOVA followed by 
least significant difference test. ** p < 0.01.
5.4.8. Effect of simultaneously inducing and inhibiting HO on the ETC of 
IFNy/LPS treated astrocytes
Since treating astrocytes with IFNy/LPS + hemin appears to reverse the 
inhibition of complex IV seen after IFNy/LPS treatment (Table 5.2., Figure
5.4.), it is feasible that induction of HO-1 by hemin is protective. Treating 
simultaneously with hemin and SnPPIX to inhibit HO may be expected to 
reverse this protective effect. Astrocytes were treated with media alone (control) 
or media supplemented with lOOU/ml IFNy/ lpg/ml LPS + lOOpM hemin + 
20pM SnPPIX. When expressed against a protein baseline although there were 
no significant differences compared to control in any of the ETC complexes 
including complex IV all activities did appear to be somewhat lower (Table
5.3.), Although complex I activity was higher it was not significantly so. When 
assessed against citrate synthase activity however complex I was significantly 
higher than control (Figure 5.8) (vs citrate synthase: control; 0.201 ± 0.01, 
IFNy/LPS+hemin+SnPPIX; 0.396 ± 0.01 (n = 3-4 independent cell preparations) 
p < 0.05)). No significant differences were seen in complex II/III or complex IV 
when expressed against citrate synthase.
5.4.9. Effect of simultaneously inducing and inhibiting HO on GSH levels in 
IFNy/LPS treated astrocytes
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In astrocytes treated with IFNy/LPS + hemin GSH levels are more than two-fold 
higher than control levels (Figure 5.7.). To investigate GSH levels using this
Comp I Comp II/III Comp IV Citrate synth.
Treatment nmol/min/mg nmol/min/mg ^/min/mg nmol/min/mg
Control 32.2+1.8 15.0 + 2.3 2.12 + 0.22 160.5 + 9.5
IFNy/LPS+hemin+SnPPIX 53.0 + 3.6 9.9 ±0.4 1.55 + 0.21 137.9 + 8.4
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Figure 5.8. Effect of simultaneously stimulating and inhibiting HO on the 
ETC in IFNy/LPS treated astrocytes
Astrocytes were treated with media alone (control) or media supplemented with 
lOOU/ml IFNy/ 1 pg/ml LPS + lOOpM hemin + 20pM SnPPIX for 24 hours, then 
ETC complex activities were assayed in cellular homogenates. Activities were 
expressed against a protein baseline or vs citrate synthase activity . There were 
no significant differences in activities when expressed against a protein baseline, 
however when expressed against citrate synthase there was a significant increase 
in complex I activity in cells treated with IFNy/LPS+hemin+SnPPIX compared 
to control. Data was mean ± SEM (n = 3-4 independent cell preparations).
Statistical significance was determined by one-way ANOVA followed by least 
significant difference test compared to control. * p < 0.05.
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same treatment but with SnPPIX added to inhibit HO enzyme activity, cells were 
treated with media alone (control) or media supplemented with lOOU/ml 
IFNy/lpg/ml LPS + lOOpM hemin + 20pM SnPPIX for 24 hours. Intracellular 
GSH levels in these cells were not significantly different from each other (Figure 
5.9.) (control; 21.4 ± 3.6 nmol GSH/mg protein, IFNy/LPS+hemin+SnPPIX, 
23.0 + 3.0 GSH nmol/mg protein (n = 4 -6 independent cell preparations)).
5.4.10. Effect of simultaneous induction and inhibition of HO on 
nitrite/nitrate levels in media of astrocytes treated with IFNy/LPS
To see if simultaneously inducing and inhibiting HO had any effect on nitrite 
accumulation in the media of IFNy/LPS treated astrocytes, cells were treated 
with media alone (control), media supplemented with lOOU/ml IFNy/lpg/ml 
LPS + lOOpM hemin or IFNy/LPS + hemin + 20pM SnPPIX for 24 hours. 
Nitrite levels were measured after any nitrate had been converted to nitrite 
(described in section 2.4.1), Nitrite production in astrocytes treated with 
IFNy/LPS + hemin or + hemin and SnPPIX showed nitrite significantly higher 
than control, but not significantly different from each other (Figure 5.10.) 
(control; 30.8 ± 9.7 nmol nitrite/mg protein, IFNy/LPS+hemin; 68.6 ±10.1 nmol 
nitrite/mg protein, IFNy/LPS + hemin + SnPPIX; 79.1 ±3. 5  nmol nitrite/mg 
protein (n = 3 -5 independent cell preparations) p < 0.05).
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Figure 5.9. Effect of simultaneously inducing and inhibiting HO in 
astrocytes treated with IFNy/LPS on GSH levels
Astrocytes were treated with media alone (control) or lOOU/ml IFNy/1 gg/ml 
LPS + lOOpM hemin + 20pM SnPPIX for 24 hours. Intracellular GSH levels 
were then determined. Treating with IFNy/LPS + hemin + SnPPIX did not cause 
a significant change in the level of GSH compared to control. Values are mean ± 
SEM (n = 4-6 independent cell preparations). Statistical significance was 
determined by one-way ANOVA followed by least significant difference test.
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Figure 5.10. Effect of simultaneously inducing and inhibiting HO in 
astrocytes treated with IFNy/LPS on nitrite/nitrate levels in media
Astrocytes were treated with media alone (control), lOOU/ml IFNy/lpg/ml LPS + 
lOOpM hemin or IFNy/LPS + hemin + 20pM SnPPIX for 24 hours. Media was 
removed and nitrite levels were measured after nitrate was converted to nitrite as 
described previously. Treatment with IFNy/LPS + hemin and IFNy/LPS + hemin 
+ SnPPIX caused nitrite levels in media to be significantly raised compared to 
control. Data are mean ± SEM (n = 3 -5 independent cell preparations).
Statistical evaluation was by one-way ANOVA followed by least significant 
difference test. * p < 0.05.
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5.4.11. The effect of L-BSO treatment on GSH levels in astrocytes
In order to deplete GSH levels in astrocytes they were treated with L-BSO for 24 
hours before L-BSO medium was removed, cells washed and media replaced 
with media alone (control), lOOU/ml IFNy/lgg/ml LPS, or IFNy/LPS + lOOpM 
hemin, for a further 24 hours. GSH levels were depleted significantly compared 
to non L-BSO treated astrocytes in all cases (Figure 5.11).
5.4.12. The effect of L-BSO treatment on the ETC of astrocytes treated with 
IFNy/LPS ± hemin
Cells depleted of GSH as discussed in the previous section, were treated with 
with media alone (control), lOOU/ml IFNy/lpg/ml LPS, or IFNy/LPS + lOOpM 
hemin for 24 hours before being assayed for ETC activity. When expressed 
against protein concentration or citrate synthase activityof the cells there were no 
significant differences in activities caused by any of the treatments (Table 5.4).
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Figure 5.11. Intracellular GSH levels in astrocytes treated with IFNy/LPS 
and hemin ± L-BSO
Astrocytes were treated with or without 0.5mM L-BSO for 24 hours after which 
time the medium was removed, cells washed twice with HBSS and incubated for 
a further 24 hours with media alone (control), media supplemented with lOOU/ml 
EFNy/lpg/ml LPS or IFNy/LPS + lOOpM hemin. Intracellular GSH levels were 
then determined. Treatment with L-BSO caused a significant drop in GSH levels 
in all cases compared to non L-BSO treated astrocytes (shown for comparison).
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Treatment Complex I 
nmol/min/mg
Complex II/III 
nmol/min/mg
Complex IV 
^/min/mg
Citrate synth. 
nmol/min/mg
Control 23.6 + 4.1 11.8 + 2.7 1.8 ±0.2 117.5+15.7
IFNy/LPS 22.6 ± 2.9 11.5 + 0.8 1.4 ±0.3 105.1+7.4
IFNy/LPS+hemin 27.1+7.1 13.2 + 2.2 1.6 ±0.2 90.8 + 6.5
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Figure 5.12. ETC complex activity of astrocytes after L-BSO treatment 
when astrocytes are treated with IFNy/LPS and an inducer of HO
GSH depleted astrocytes were treated with media alone (control), or media 
supplemented with lOOU/ml EFNy/ 1 |ig/ml LPS or IFNy/LPS + hemin for 24 
hours before ETC complex activities were assayed in cellular homogenates. 
Activities were expressed against a protein baseline (Table 5.4) or vs citrate 
synthase activity (Figure 5.12). There were no significant differences in any 
complex activities when expressed against protein or citrate synthase activity.. 
Data was mean ± SEM (n = 4 independent cell preparations). Satistical 
significance was determined by one-way ANOVA followed by least significant 
difference test compared to control
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5.4.13. The effect of DETA-NO treatment on the astrocytic ETC treated 
with an inducer or inhibitor of HO
In order to investigate the effects of an exogenous NO exposure on astrocytes 
where the HO status of the cell is manipulated cells were treated with media 
alone (control), the NO donor DETA-NO (0.5mM), DETA-NO + lOOpM hemin 
or DETA-NO + 20pM SnPPIX. ETC complex activities were measured and 
expressed against protein or citrate synthase activity. When expressed against 
protein, complex II/III was significantly lower than controls in cells treated with 
DETA-NO + hemin and DETA-NO + SnPPIX (Table 5.5.) (Control; 15.0 ± 2.3 
nmol/min/mg protein, DETA-NO + hemin; 5.9 ± 0.6 nmol/min/mg protein, 
DETA-NO + SnPPIX; 6.5 ± 1.6 nmol/min/mg protein (n = 3 -  5 independent cell 
culture preparations) p < 0.05). When expressed against either protein or citrate 
synthase complex IV was significantly decreased in all treatments containing 
DETA-NO (Table 5.5. and Figure 5.13) (vs protein, control, 2.12 ± 0.22 
k/min/mg protein; DETA-NO, 0.69 ± 0.14 ^/min/mg protein; DETA-NO + 
hemin, 0.74 ± 0.06 k/min/mg protein; DETA-NO + SnPPIX, 0.49 ± 0.28 
k/min/mg protein (n = 3 -  5 independent cell culture preparations) p < 0.01). 
Complex I and citrate synthase activities were not significantly different to 
controls after any of the treatments. Previous work in this lab has shown that 
degraded DETA-NO has no effect on respiratory chain enzyme activities 
(personal communication, Dr A Duncan, Institute of Neurology, London).
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Treatment
Comp I 
nmol/min/mg
Comp II/III 
nmol/min/mg
Comp IV 
k/min/mg
C/Synthase
nmol/min/mg
Control 32.2 ± 1.8 15.0 ± 2.3 2.12 ±0.22 160.5 ±9.5
DETA-NO 26.2 ± 8.4 8.3 ± 1.4* 0.70 ±0.15** 144.8 ± 10.7
DET A-NO+hemin 43.2± 11.2 5.9 ± 0.6* 0.74 ±0.06** 130.9 ±9.3
DET A-NO+SnPPIX 27.3 ± 6.6 6.5 ± 1.6* 0.49 ±0.28** 110.5 ±6.6
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Figure 5.13. The effect of DETA-NO on the ETC when astrocytes are 
treated with an inducer or inhibitor of HO
Astrocytes were treated with media alone (control), media supplemented with 
0.5mM DETA-NO alone, lOOpM hemin + DETA-NO or 20pM SnPPIX + 
DETA-NO. Following 24 hours of treatment cell homogenates were assayed for 
ETC complex activity. Data were expressed against protein and citrate synthase 
activity. Treatment with DETA-NO + hemin or SnPPIX caused a significant loss 
of complex II/III activity against control when assessed against protein. All 
DETA-NO treatments caused a significant loss of complex IV activity against a 
protein baseline or citrate synthase. Data are mean ± SEM (n = 3 -5). Data was 
statistically evaluated using one-way ANOVA followed by least significant 
difference test. * p < 0.05, ** p < 0.01.
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5.4.14. The effect of DETA-NO treatment on HO-1 expression and HO 
activity
As shown in Figure 5.5. stimulation of NO production by iNOS mediated by 
fFNy/LPS causes upregulation of HO-1 expression and HO activity. Would an 
exogenous source of NO have the same effect?
Astrocytes in flasks or 6-well plates were treated with media alone (control), 
media supplemented with 0.5mM DETA-NO, DETA-NO + lOOpM hemin or 
DETA-NO + 20pM SnPPIX. Cells in 6-well plates were lysed and subjected to 
SDS-PAGE before being transferred to a nitrocellulose membrane which was 
probed with an antibody to HO-1. Cells in flasks were homogenised and assayed 
for bilirubin production as an indication of HO activity. Representative blots of 
HO-1 protein (Figure 5.14a) show that DETA-NO strongly induces expression 
of protein. DETA-NO + hemin or SnPPIX also appeared to raise expression of 
HO-1 compared to controls but not to the same extent. DETA-NO treatment 
alone caused a significant almost 4-fold increase in HO activity compared to 
control (Figure 5.14b) (Control; 21.3 ± 5.8 pmol biliubin/min/mg protein, 
DETA-NO; 75.1 ± 20.8 pmol bilirubin/min/mg protein (n = 3 -4 independent cell 
culture preparations) p < 0.01). In cells treated with DETA-NO + hemin the 
increase is still significant but smaller (Figure 5.14b) (Control; 21.3 ± 5.8 pmol 
bilirubin/min/mg protein, DETA-NO + hemin; 58.4 ± 9.6 pmol bilirubin/min/mg 
protein (n = 3 -  5 independent cell culture preparations) p < 0.05). Treating with 
SnPPIX inhibits HO activity as previously seen. Treating with degraded DETA- 
NO caused no rise in HO activity.
148
Actin
1 2 3 4
Key: 1 = Control, 2 = DETA-NO, 3 = DETA-NO + hemin, 4 = DETA-NO +
SnPPIX.
b)
c 100  «2
2■§; 80 * I
o 60 •
Q.
•i 40 *-Q
E
j= 20 *CD
DETA- DETA- Deg DETA-NODETA-NOControl
NO+hemin NO+SnPPIX
Figure 5.14. The effect of DETA-NO treatment on HO expression and 
activity in astrocytes
Astrocytes were treated with media alone (control), media supplemented with 
0.5mM DETA-NO, DETA-NO+lOOpM hemin , DETA-NO+20pM SnPPIX or 
degraded DETA-NO for 24 hours. Bilirubin production was measured, and HO-1 
expression was assessed by western blotting. Treating with DETA-NO increases 
expression of HO-1 protein alone or when combined with hemin or SnPPIX. HO 
activity is significantly increased compared to control when astrocytes are treated 
with DETA-NO alone or when treated with DETA-NO plus hemin. Data are 
mean ± SEM. Statistical evaluation was by one-way ANOVA followed by least 
significant difference test.*p < 0.05 , ** p < 0.01
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5.4.15. Nitrite/nitrate accumulation in media after astrocytes treatment with 
DETA-NO whilst HO is induced or inhibited
In order to investigate whether there were any changes to the production of NO 
by DETA-NO when HO is induced or inhibited astroytes were treated with 
media alone (control) media supplemented with 0.5mM DETA-NO, DETA-NO 
+ hemin or DETA-NO + SnPPIX for 24 hours. After this time media was 
removed, any nitrate converted to nitrite as described in section 2.4.1. and nitrite 
measured. All DETA-NO treatments caused significantly increased nitrite 
accumulation compared to control (Figure 5.15) (Control; 30.8 ±9.7 nmol/mg 
protein, DETA-NO; 176.4 ± 33.8 nmol/mg protein, DETA-NO ± hemin; 159.2 ± 
17.5 nmol/mg protein, DETA-NO + SnPPIX; 197.9 ± 28.3 nmol/mg protein(n = 
5 - 9  independent cell culture preparations) p < 0.01). None of the DETA-NO 
treatments however were significantly different from each other.
5.4.16. GSH levels in astrocytes treated with DETA-NO whilst HO is 
induced or inhibited
As described in section 5.3.6. in astrocytes treated with IFNy/LPS + hemin, 
levels of intracellular GSH rise significantly. In order to see if DETA-NO 
treatment has the same effect astrocytes were treated with media alone (control), 
0.5mM DETA-NO, DETA-NO + lOOpM hemin or DETA-NO ± 20pM SnPPIX 
for 24 hours after which time GSH levels were measured . Treatment of cells 
with DETA-NO + hemin caused a significant, more than two-fold increase in
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Figure 5.15. Nitrite/nitrate accumulation in media after treatment with 
DETA-NO and an inducer or an inhibitor of HO
Astrocytes were treated with media alone (control), media supplemented with 
0.5mM DETA-NO alone, lOOpM hemin + DETA-NO or 20pM SnPPIX + 
DETA-NO for 24 hours. Accumulated nitrite in media was determined after 
nitrate had been converted to nitrite as described previously. All treatments 
containing DETA-NO caused nitrite levels to be significantly raised compared to 
control. Data are mean ± SEM (n = 5 -  9 independent cell preparations). Data 
was statistically evaluated by one-way ANOVA followed by least significant 
difference test. ** p < 0.01.
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intracellular GSH levels (Figure 5.16) (Control; 21.4 ±3 . 6  nmol/mg protein, 
DETA-NO ± hemin; 58.7 ± 7.7 nmol/mg protein (n = 4 -  6 independent cell 
culture preparations) p < 0.01). Treatment with DETA-NO alone or DETA-NO ± 
SnPPIX did not significantly change GSH levels compared to control. Treatment 
of astrocytes with degraded DET A-NO does not result in any significant change 
in GSH levels as compared to untreated controls. (Gegg et al., 2003).
5.5. Discussion
NO is rapidly converted to nitrate (NO3 ) and nitrite (NO2 ) after synthesis and 
release from astrocytes, therefore levels of these stable breakdown products in 
culture media from NO producing astrocytes is often used as an index of NO 
production (McNaught & Jenner, 2000a), and can be further postulated to be an 
index of iNOS activity .
Astrocytes in this study, when treated with interferon gamma (IFNy) plus 
lipopolysaccaride (LPS) show stimulated iNOS activity as demonstrated by 
nitrite and nitrate release into media. Although IFNy and LPS stimulate iNOS 
when used individually, Bolanos et al, (1994) showed that using both IFNy and 
LPS potentiated the release of nitrite and nitrate as compared to release from 
astrocytes treated with either agent alone. Similarly it was found that incubating 
with both IFNy plus LPS gave a 20-fold higher NOS activity than that found by 
Galea et al, (1992) after treatment with LPS alone. This agrees with the proposed 
idea that cytokines may mediate the induction of NOS activity by LPS (Murphy 
etal., 1993, Simmons and Murphy, 1993).
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Figure 5.16. GSH levels in astrocytes treated with DETA-NO and an 
inhibitor or inducer of HO
Astrocytes were treated with media alone (control), media supplemented with 
0.5mM DETA-NO, lOOpM hemin + DETA-NO or 20pM SnPPIX + DETA-NO 
for 24 hours after which time cellular GSH levels were determined. Treatment 
with hemin + DETA-NO caused a significant rise in cellular GSH compared to 
control. Data are mean ± SEM (n = 4 -  6 independent cell preparations). 
Statistical evaluation was by one-way ANOVA followed by least significant 
difference test. ** p < 0.01.
153
Bolanos et al (1994) found that treating with IFNy/LPS for 18 hours caused a 
25% inhibition in the activity of complex IV; in the current study astrocytes were 
treated for 24 hours, and at this point a 75% inhibition was seen. Some of 
the increased inhibitory effects could be due to the longer incubation, although 
Bolanos et al., (1994) found that treating the cells up to 36 hours in IFNy/LPS 
only caused a 56% inhibition of complex IV. The discrepancy may be caused by 
a difference in treatment regime, where in the current study the treatment media 
was applied at time 0 and remained for the whole of the treatment time, whereas 
in Bolanos et al (1994) media was replaced after 18 hours with fresh media 
containing IFNy/LPS. It may be that factors in the media affect the amount of 
inhibition seen. In this study it was also found that IFNy/LPS treatment caused an 
apparent increase in complex I activity when assessed against a protein baseline, 
which became significant when assessed against citrate synthase activity. It has 
been reported that low grade oxidative stress can upregulate complex I activity in 
glial cells (Vasquez et al., 2001) by increasing expression of the complex I ND6 
subunit, a mitochondrially encoded subunit associated with proton translocation 
across the inner mitochondrial membrane. In this experimental situation 
oxidative stress could feasibly occur due to the inhibition of complex IV; Sipos 
et al.,(2003) report that in isolated nerve terminals production of ROS may occur 
when complex IV is more than 70% inhibited. Theoretically, once complex I 
acvtivity is upregulated then further electron leak could occur due to the inability 
of the other complexes to transport electrons quickly enough and therefore the 
situation could perpetuate itself.
It has been previously shown that treating various cells with IFNy and /or LPS 
not only induces iNOS but also causes an upregulation of HO-1 protein, i.e. glial
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cells (Kitamura et al., 1998), glomerular mesangial cells (Datta et al., 1999). 
However it is not clear how this upregulation relates to enzyme activity. Having 
established that in the astrocytes used in this study, treatment with IFNy/LPS 
causes nitric oxide to be produced, inhibition of complex IV to occur and an 
increase in HO-1 protein, it was then necessary to determine if the HO protein 
was enzymatically active and investigate whether inhibition or further induction 
of HO would have any effect on the IFNy/LPS mediated inhibition of complex 
IV.
Treatment with IFNy/LPS caused an approximately two-fold upregulation of HO 
activity that was inhibited by treating with L-NIL, this suggests that the increase 
in activity is mediated by NO and not IFNy/LPS treatment. This indicates that 
when complex IV is inhibited by IFNy/LPS, HO and it’s breakdown products 
will also be present. Reports have shown that inhibiting HO can in some cases be 
protective e.g. concurrent treatment of cultured astroglial cells with H2O2 and the 
HO inhibitor tin mesoporphyrin protected cells against the cytotoxic effects of 
H2O2 treatment (Dwyer et al., 1988) and treatment of epithelial cells with an HO 
inhibitor partially reversed the toxic effects of a 24 hour H20 2 challenge (Da 
Silva et al., 1996). In the present study cells treated with IFNy/LPS and SnPPIX 
displayed a significant loss of complex IV activity when compared to controls 
but this inhibition was less than that seen when treating with IFNy/LPS alone at 
approximately 43%, opposed to 75%. Treatment with hemin and IFNy/LPS 
however, completely prevented the inhibition. Reasons for the apparent 
protection afforded by hemin can be postulated. HO activity measured after this 
treatment was significantly greater than that measured with IFNy/LPS treatment
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alone, it is a possibility that increased bilirubin production could have a powerful 
antioxidant effect. It is known that bilirubin is a scavenger of peroxy radicals 
such as peroxynitrite (Stocker et al., 1987) which could be formed in this 
environment from NO and superoxide which may be present due to the apparent 
upregulation of complex I or inhibition of complex IV. It has also been observed 
that NOS also produces O2" and/or H2O2 in addition to NO (Heinzel et al., 1992; 
Pou et al., 1992). Expression of HO-1 after treatment with IFNy/LPS plus hemin 
appears to be greater than that seen when treating with IFNy/LPS alone or 
IFNy/LPS plus SnPPIX and this could be an additional reason for the protective 
effect seen. Taylor et al., (1998) report that actual induction of HO-1 protein 
rather than activity of the enzyme exerted protective effects against hyperoxic 
lung injury in vivo. In this case it may be expected that treatment with IFNy/LPS 
plus SnPPIX would prevent the inhibition of complex IV, since SnPPIX has been 
shown to enhance synthesis of HO-1 protein whilst potently inhibiting enzyme 
activity (Sardana & Kappas, 1987), and it could be argued that inhibition is less 
in this instance, but not completely abolished. Examination of nitrite/nitrate 
accumulation in media show that adding hemin to IFNy/LPS gives a similar 
result to using IFNy/LPS alone, but adding SnPPIX to IFNy/LPS causes an 
increased nitrite/nitrate production. Jozkowicz & Dulak (2003) report that in 
vascular smooth muscle cells SnPPIX increased IL-ip stimulated activity of 
iNOS and induced some nitrite accumulation in unstimulated cells. It is possible 
that in astrocytes stimulated with IFNy/LPS, SnPPIX can further stimulate iNOS 
causing increased NO production, although media from astrocytes treated with 
SnPPIX alone did not show increased nitrite/nitrate production as shown in 
Figure 4.11b.
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GSH levels were significantly higher in cells treated with IFNy/LPS plus hemin 
compared to control cells or those treated with IFNy/LPS plus SnPPIX. Since 
treatment of astrocytes with IFNy/LPS alone does not raise GSH levels it may be 
that hemin is the cause since as mentioned previously it can act as an oxidant and 
oxidant stresses can cause upregulation of glutamate-cysteine ligase, the first and 
rate limiting enzyme in the GSH synthesis pathway (Tian et al., 1997; 
Moellering et al., 1998; Iwata-Ichikawa et al 1999; Gegg et al.,2005). Since 
GSH has been implicated in protecting the enzymes of the electron transport 
chain from oxidative stress (Bolanos et al., 1995; Barker et al., 1996) this may 
have some part to play in the prevention of inhibition of complex IV and the 
reason why treatment with SnPPIX is not protective to the same extent.
Complex activities, GSH levels and nitrite/nitrate accumulation were examined 
in IFNy/LPS stimulated astrocytes treated with both hemin and SnPPIX to 
examine the effects of inducing and inhibiting HO simultaneously. In this case it 
appeared that complex II/III and IV were lower than controls, but this was not 
significant against either protein or citrate synthase activity. Complex I was 
significantly higher once more against citrate synthase and this could once again 
be explained by an oxidative stress caused by hemin. Nitrite/nitrate accumulation 
was not significantly different from that seen in astrocytes treated with IFNy/LPS 
alone or IFNy/LPS plus hemin. Perhaps surprisingly, GSH levels were not 
significantly different to control levels. As mentioned previously GSH levels and 
HO-1 expression appear to be linked as a concerted stress response in the cell, 
with depletion of GSH leading to an upregulation of HO-1 protein (Ewing & 
Maines, 1993; Oguru et al., 1996; Ryter & Choi 2005) and addition of GSH and
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its precursors causing a decrease in expression and activity (Foresti et al., 1997). 
It may be expected that inhibiting HO activity would lead to an increase in GSH 
levels, however this may not be the case since the HO reaction itself can 
potentially generate hydrogen peroxide (H2O2), as a significant metabolic side 
product, as demonstrated by Noguchi et al., (1983) Thus HO activity is a 
possible source of OH* because both H2O2 and Fe2 are released in the same 
microenvironment. Hence by inhibiting HO in this case a potential source of 
ROS is removed. Given the evidence obtained so far it could be possible that 
when astrocytes are treated with IFNy/LPS alone, although HO-1 activity is 
induced, any oxidative stress arising is not enough to stimulate further GSH 
synthesis and so no further protection is afforded and complex IV is inhibited. 
However treatment with hemin and IFNy/LPS causes further HO activity to be 
stimulated and together with the possible oxidative nature of hemin a threshold is 
reached whereby GSH synthesis is stimulated and protection occurs. An attempt 
to verify the protective nature of GSH was made by depleting astrocytic 
glutathione and treating with IFNy/LPS ± hemin, to see if adding hemin was still 
protective. The depletion of glutathione was effective with depletion of >80% 
GSH, however the measurement of ETC activities on GSH depleted astrocytes 
shows no significant differences to depleted control astrocytes, whatever 
treatment was given. All complex activities were slightly lower than undepleted 
astrocytes but the only significant differences were in complex I where both 
IFNy/LPS treated and IFNy/LPS + hemin GSH depleted astrocytes showed 
significantly lower complex I values against a protein baseline, than their 
undepleted counterparts. Within the group differences caused by treatments were 
not found. Unfortunately in this case media was not analysed for nitrite/nitrate to
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ensure that IFNy/LPS were active and stimulating iNOS, if NO were not being 
formed it could explain the lack of inhibition of complex IV. Another possibility 
is that depleting GSH causes another protective mechansim to come into effect, 
indeed depletion of GSH has been shown to upregulate HO-1 (Ewing & Maines, 
1993; Oguru et al., 1996; Ryter & Choi 2005). Western blot analysis of 
IFNy/LPS treated GSH depleted astrocytes could be carried out to show if this is 
the case. Other studies have shown that depleting astrocytic GSH in 
glial/neuronal co-culture studies reduces neuronal viability whilst leaving 
astrocytes largely unaffected (Drukarch et al., 1997, Gegg et al., 2005). 
Stimulation of iNOS with IFNy/LPS causes endogenous release of NO within the 
cell and the subsequent inhibition of complex IV discussed above. DETA-NO is 
a nitric oxide donor which can provide an exogenous source of NO to cells in 
culture and given the apparent protective effect of treating IFNy/LPS activated 
astrocytes with hemin it was considered conceivable that this same protection 
could be seen against an exogenous source of NO. DETA-NO when suspended 
in aqueous solution releases NO at a constant rate (reaction 5.1) with a half-life 
of at least 24 hours (Keefer et al., 1996).
(5.1)
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Previous work in this lab (Gegg, 2003) has shown that 0.5mM DETA-NO in 
astrocyte medium generates a steady state NO concentration of 0.93 ± 0.07 pM 
at 37°C. This was observed within 30 minutes of the DETA-NO being prepared 
and was constant for at least 24 hours.
The effect of 0.5mM DETA-NO on the electron transport chain was similar to 
that of IFNy/LPS treatment in that complex IV was significantly inhibited 
compared to control, but also in this case complex II/III was inhibited too. In this 
case treating with hemin at the same time did not give any protective effects, in 
fact all treatments containing DETA-NO significantly lowered complex II/III 
against protein and complex IV against either variable. HO expression and 
activity were both present, in fact DETA-NO alone appeared to induce HO-1 
protein to a much greater extent than when combined with either hemin or 
SnPPIX. This is contrary to reports that NO inhibits HO activity (Willis et al., 
1995; Juckett et al., 1998,) and that NO donors prevent induction of HO-1 by 
hemin (Juckett et al., 1998). Indeed although it appears that in the current study 
HO activity is lower when DETA-NO plus hemin are incubated with astrocytes 
there is not a significant difference and activity is still more than twice that of 
controls. Different NO-donors were used in the Willis paper which may account 
for some differences, also brain homogenate was used rather than cultured cells; 
in the Juckett paper, DETA-NO was used but the hemin incubation was lOpM 
for 1 hour before media was replaced with either untreated media or media 
containing DETA-NO. It may be significant that incubation of hemin and DETA- 
NO was not simultaneous, it may also be significant that the cells used were 
endothelial cells not astrocytes. Conversely, Foresti et al, (2003) report an
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increase in HO activity when treating endothelial cells with DETA-NO that is 
further increased when hemin is also used. However in the present study this is 
not seen. The experimental protocols differ though and cell type so this could 
conceivably explain the differences. Nitrite/nitrate accumulation in media from 
DETA-NO treated astrocytes shows much higher levels than that seen when 
iNOS is stimulated, however this is not unexpected since in this situation all of 
the NO is released directly into the medium, not via cell membranes or 
intracellular targets such as the ETC or GSH as would be the case with iNOS 
generated NO. Also as mentioned previously a detectable release of lpM NO is 
seen after 30 minutes of addition of DETA-NO to media (Gegg, 2003) so it is 
likely that NO release is occurring from very early on in the incubation, iNOS 
stimulation and subsequent release of NO is likely to take longer. Taking these 
factors into account, higher levels of NO may be expected to be available to 
inhibit the ETC more quickly, when treating with an NO-donor, and therefore a 
possible cause for the increased ETC inhibition seen in DETA-NO treated 
astrocytes after the same period of treatment as the IFNy/LPS treated cells. It 
could possibly be expected, that if inhibition of the ETC is occurring via 
nitrosative stress, then GSH levels could be raised as GSH synthesis is 
stimulated; however, only hemin plus DETA-NO caused a significant rise in 
GSH levels. DETA-NO alone or with SnPPIX levels were similar to control. 
Despite this raise in GSH levels hemin does not apparently prevent inhibition of 
the ETC in astrocytes when used in conjunction with DETA-NO treatment. Since 
it has been suggested a rise in GSH levels acts as a protective mechanism when 
IFNy/LPS stimulated astrocytes are treated with hemin it is not clear why it is not 
so in this case. A possible answer may be that NO released by DETA-NO reacts
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very quickly with bilirubin and depletes it, thus although GSH levels have risen 
antioxidant defenses are lowered due to lower levels of bilirubin. Kaur et al., 
(2003) show that various nitric oxide releasing species are able to interact with 
and decompose bilirubin very quickly. Kaur et al., (2003) report that 
incubating 40jlaM DEA-NO with 5pM bilirubin caused the disappearance of the 
bilirubin within 90 minutes. Further to this Foresti et al., (2003) report that haem 
degradation products appear to modulate the action of NO donors by accelerating 
and increasing the release of NO. Treatment of cells for 24 hours with hemin 
would certainly mean that haem degradation products would be present, however 
amounts of nitrite and nitrate were not significantly higher in DETA-NO treated 
cells as apposed to DETA-NO only treated cells. Another reason could be a 
delay in release of NO via iNOS in IFNy/LPS treated cells which is not seen (or 
certainly not seen as much) when DETA-NO is used as the NO “donor”. In order 
to see if this is this case it would be interesting to look at a time course of 
complex IV inhibition using both IFNy/LPS and DETA-NO. Bolanos et al.,
(1994) report that complex IV inhibition occurs in astrocytes after 18 hours of 
IFNy/LPS treatment and previous work in this lab (Gegg, 2003) has shown that 
DETA-NO treatment also inhibits complex IV after 18 hours of treatment, but 
perhaps there is a timepoint before this when inhibiton is seen with DETA-NO 
treatment but not activation of iNOS.
5.6. Conclusions
Both an endogenous source (iNOS), and an exogenous source of NO cause 
inhibition of the ETC in astrocytes. Simultaneous stimulation of iNOS plus
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hemin appear to reverse this inhibition, however simultaneous incubation of 
DETA-NO treated astrocytes with hemin does not. A number of factors may be 
involved in this apparent hemin mediated protection of the ETC. Upregulation of 
HO-1 protein and HO activity may be one factor. Treatment of astrocytes with 
hemin causes HO-1 to be induced and may also cause an oxidative stress due to 
the oxidative nature of the hemin molecule, this oxidative stress along with the 
potential H2O2 generating properties of the HO reaction may cause upregulation 
of GSH synthesis when a certain threshold is reached, thereby proving 
protective. When DETA-NO is used instead of stimulation of iNOS it may be 
that although there is HO induction and activity, rapid NO release from DETA- 
NO quickly depletes bilirubin , so a greater nitrosative stress is incurred. 
Although GSH is stimulated through the same pathway mentioned previously, 
the defenses may not be robust enough to prevent damage from occurring.
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Chapter 6
General Discussion and 
Conclusions
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Previous studies have documented increased HO-1 expression in many 
neurodegenerative disorders (for review see Schipper, 2004). It has also been 
documented that HO-1 expression is upregulated to high levels in glial cell 
populations as a response to oxidative stress (Ewing & Maines, 1991; Ewing et 
al., 1992; Ewing & Maines., 1993; Geddes et al., 1996; Turner et al., 1998). 
Oxidative stress as a cause/consequence of neurodegeneration is a subject being 
researched by many different groups. This together with the increasing 
awareness of the importance of astrocytes in providing support to neurones and 
the fact that investigations to date on actual HO activity in astrocytes are few, 
makes the study of HO-1 expression and activity in astrocytes in reponse to 
oxidative and nitrosative stress important. Although HO-1 expression in 
astrocytes has been reported by various groups (Schipper, 1999; Ham & 
Schipper, 2000; Bidmon et al., 2001; Lu & Ong, 2001; Mehindate et al., 2001) a 
link to activity has been investigated far less frequently (Scapagnini et al., 2002., 
Huang et al., 2005)
Chapter 3 focused on the assay of haem oxygenase, and it was clear that there 
were certain steps in the assay process that are crucial. The liver cytosol extract 
used as a source of biliverdin reductase in the assay needed to contain as little 
contaminating blood as possible, to prevent haemoglobin interference in the 
assay, as reported by McNally et al., (2004). Although many published works 
quote incubation times for the assay as an hour, in this investigation using 
astrocytes, activity was only linear up to 15 minutes of incubation (Figure 3.3), 
so this was the time scale used. Although as mentioned there are other methods 
for assaying HO activity, this is a method that does not require radioactive 
reagents or lengthy preparatory proceedures. The disadvantage of all the methods
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of assaying HO activity is that it is total activity, the combined activity of HO-1 
and HO-2 (and of course any other isoforms not identified yet) that are measured 
. The fact that HO-2 is constitutive (Maines, 1997) means that there will always 
be some contribution from this isozyme, but the fact that the only known 
chemical inducers of HO-2 are adrenal glucocorticoids suggest that any increase 
seen in HO activity when not using these agents is likely to be due to HO-1. 
Further, it has also been reported that HO-2 in the brain is mainly expressed in 
neurones (Ewing & Maines, 1992), so it may well be that the majority of HO 
activity seen in astrocytes is HO-1. Antibodies have been raised against both HO 
isoforms (Maines et al., 1996; Trakshel et al., 1996) which are reported not to 
cross react so it may be possible to immunoprecipitate each isoform from a cell 
culture homogenate and examine the contribution via an appropriate assay.
Hemin was used as both an inducer of HO-1 and as a substrate in the HO assay, 
and the fourth chapter of this thesis concentrated on the effects that hemin had 
on cell viability, total HO activity and HO-1 expression, mitochondrial ETC 
enzyme activity, GSH status and nitrite/nitrate production in rat astrocytes. 
Hemin can be a source of cell injury to glial cells within the brain due to 
haemorrhage, when haemoglobin spontaneously, nonenzymatically converts to 
methaemoglobin (Huang et al., 2002) from which hemin readily dissociates 
(Bunn & Jandl., 1968; Hebbel & Eaton., 1989). The results of this chapter 
showed no significant loss of cell viability using lOOpM hemin, but a robust 
upregulation of HO-1 protein and a corresponding increase in total HO activity 
(Figure 4.6.). Although HO activity was maximal at 6 hours of treatment there 
was still an approximately 3.5 fold increase in activity after 24 hours of 
treatment. All other parameters measured showed no significant differences
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against control except for an increase in the levels of astrocytic GSH at 18 hours 
of hemin treatment and as mentioned previously this could be due to a decreased 
HO activity causing a transient oxidative stress which increases GSH synthesis, 
which is known to be upregulated by oxidative stress (Tian et al., 1997; 
Moellering et al., 1998; Iwata-Ichikawa et al., 1999; Gegg et al., 2005). This 
chapter showed that after 24 hours of hemin treatment, apart from a change in 
HO activity and expression all other measured parameters were not significantly 
different to control. The inhibition of HO activity was investigated using two 
metalloporphyrins, ZnPPIX and SnPPIX. ZnPPIX was discarded due to apparent 
toxic effects at the concentration used. Inhibition of HO activity was 
successfully achieved by using SnPPIX, which had no other effects on astrocytes 
apart from causing an increased complex I activity when used in conjunction 
with hemin, and an upregulation of HO-1 protein. Use of metalloporphyrin 
inhibitors has been a common feature of HO research, however recent reports 
have suggested results achieved using them should be viewed with some caution 
due to effects they may have on the cell unrelated to HO inhibiton (Jozkowicz & 
Dulak, 2003) It has been reported that SnPPIX alone can increase basal levels of 
nitrite/nitrate accumulation (Jozkowicz & Dulak, 2003), that was not the case 
seen in the current study and it may well be that responses are cell type specific 
and each case needs to be examined on its merits. Nonetheless other methods of 
preventing HO activity may be able to remove possible non-specific actions and 
they should be investigated where possible and will be discussed in the future 
work section.
The second part of this thesis focused on manipulating the HO status of 
astrocytes activated by IFNy/LPS. The relevance of the induction of iNOS and
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NO to neurodegeneration has been well documented (for review see Stewart & 
Heales, 2003), and this thesis has demonstrated that activating iNOS using 
IFNy/LPS also activates the HO-1 pathway giving both enhanced expression of 
HO-1 protein and an increase in total HO activity (Figure 5.3 ). It was initially 
hypothesised that it could be feasible that CO generated by HO activity may 
play a part in the reversible and irreversible inhibition of complex IV shown by 
Bolanos et al., (1994) and Brown et al., (1995). HO activity was enhanced and 
inhibited to determine whether its action was protective or harmful, and certainly 
co-incubating astrocytes with inducers of iNOS and HO did prove to alleviate the 
irreversible NO-mediated inhibition of complex IV retaining enzyme activity at 
control levels. If this was an effect of increased HO activity it may be expected 
that inhibiting HO activity might make the inhibition more extensive. This was 
not the case in this investigation. IFNy/LPS activated astrocytes treated with 
SnPPIX still showed complex IV inhibition, but not to as great an extent as 
IFNy/LPS treated cells alone, although the difference between the two treatments 
was not significantly different. This makes dissecting out the actual protective 
mechanism difficult, but does indicate that in these circumstances HO-1 
induction is not a cause of further irreversible inhibition to complex IV. As well 
as preventing the inhibition caused by IFNy/LPS, adding hemin also caused an 
increase in GSH levels in the cell. (Schematic:Figure 6.1.) This is actually 
contrary to reports that addition of GSH or its precursors causes a decrease in 
HO-1 expression and activity (Foresti et al., 1997) since in this thesis the data 
shows an increase of GSH with an increase of HO activity. It is suggested that 
this is due to the combined effect of two oxidative stresses -  the effect of hemin 
and that of the HO reaction itself, this is made more plausible by the fact that
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astrocytes treated with hemin, IFNy/LPS and SnPPIX do not show the rise in 
GSH that occurs when hemin and IFNy/LPS are used alone. In the former case 
HO activity is inhibited by SnPPIX thereby removing the majority of a possible 
ROS generating reaction.
An exogenous source of NO appeared to be much more damaging to the 
mitochondrial ETC (Figure 5.13.) even if HO-1 was induced and despite the fact 
that treating with DETA-NO and hemin caused GSH levels to rise to a similar 
extent as seen when treating with hemin and IFNy/LPS (Figure 5.7. and Figure
5.16.), As discussed in chapter 5 this may be as a result of the very fast reaction 
between the NO and bilirubin (Kaur et al., 2003) or the fact that haem 
degradation products are able to modulate the action of NO donors by 
accelerating and increasing the release of NO as suggested by Foresti et al., 
(2003), thus depleting this anti-oxidant too quickly for protection to occur. It is 
also relevant that using an NO donor almost immediately exposes astrocytes to 
NO at a concentration that may not be actually occuring inside the cell even 
though electrode studies have shown comparable concentrations under 
experimental “ideal” conditions (Brown et al., 1995). For maximal NO 
production when iNOS is stimulated L-arginine must not be limiting and all 
required co-factors must be available . (Alderton et al., 2001; Aktan, 2004). NO 
release by DETA- NO may represent an overwhelming nitrosative stress as 
demonstrated by the fact that after 24 hours there is already evidence of 
inhibition to complex II/III, which is not seen in IFNy/LPS treated cells until 36 
hours of treatment (Bolanos et al., 1994) and occurs without the activation of 
iNOS which could be relevant since there are postulated to be interactions
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IFNy/LPS
iNOS HO-1
•NO
RNS
Bilirubin
b)
IFNy/LPS + hemin
ROS?iNOS
HO-1
CO
NO
bilirubin
RNS
GSH
Figure 6.1. Proposed schematic for events occurring when astrocytes are 
treated with a) IFNy/LPS alone or b) IFNy/LPS + hemin.
In a) HO-1 is induced and activity is stimulated but inhibition of complex IV of 
the ETC occurs. In b) HO-1 activity is more significantly raised , GSH levels are 
raised and protection is afforded.
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between the NOS and HO systems. It is possible that induction of HO-1 
modulates NO production in a number of ways (Maines, 1997). NOS is a 
haemoprotein and HO-1 could accelerate its degradation. Because NOS is a 
haemoprotein of P450 type and cytochromes P450 in intact or denatured form, 
can act as substrates for both HO-1 and HO-2 (Kutty & Maines, 1984) then 
increased HO activity may accelerate the turnover of NOS. CO could also bind to 
the existing NOS and inactivate the enzyme, both neuronal and macrophage NOS 
have been shown to bind CO (White & Marietta, 1992; McMillan et al., 1992).
In conclusion the work in this thesis has demonstrated a robust method for 
measuring HO activity in astrocytes. It has been demonstrated that HO-1 protein 
and total HO activity can be upregulated in astrocytes by both hemin treatment 
and by IFNy/LPS treatment, leading to the assumption that when astrocytes are 
activated by IFNy/LPS there is a corresponding HO activity in addition to iNOS 
activity. In view of the postulated pathogenic overproduction of NO and 
inhibiton of the mitochondrial ETC in some neurodegenerative diseases this is 
relevant to understanding the mechanisms of mitochondrial dysfunction. Further 
induction of HO-1 in activated astrocytes by use of hemin has been shown to 
prevent the irreversible NO mediated inhibiton of complex IV, and this apparent 
protection is postulated to be a combined effect of hemin mediated HO action 
and GSH upregulation. Inhibition of HO in IFNy/LPS stimulated cells does not 
return complex IV to control levels therefore it can be postulated that in this 
instance HO does not have a part to play in the NO mediated inhibiton of 
complex IV in rat astrocytes. Certainly though, interactions between the systems 
appear to occur and further study of these interactions will enable a greater
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understanding of the mechanisms of neurodegenerative disease and the role that 
HO plays.
Suggested future work
The work in this thesis has concentrated on induction of various enzyme 
pathways via chemical means, to complement this it should be possible to 
approach the problem from a more molecular biological perspective. 
Overexpression of HO-1 has been demonstrated in rat astroglia by transient 
transfection of the human HO-1 gene (Schipper, 1999). By using over-expression 
of HO-1 rather than further induction using hemin it may be possible to remove 
any “oxidant” effects that hemin may exert. On a similar note since the use of 
HO inhibitors can have non-specific effects (Grundemar & Ny, 1997; Jozkowicz 
et al.,2003) the use of small interfering RNA could be employed to knock-down 
the HO-1 gene and examine astyrocytic responses to iNOS induction.
Transgenic HO-1'' mice have also been produced (Poss & Tonegawa, 1997; 
Kapturczak et al., 2004), and these could also be a useful tool to examine further 
the effects of iNOS activation on astrocytes or indeed the whole brain.
Using knock outs could also be used to examine the contribution of the products 
of haem breakdown to either protection or damage of the ETC. Recently much 
research has focused on physiological roles for CO (for review see Ryter et al., 
2004) including signalling and anti-infammatory effects and further to this a 
group have synthesised CO releasing molecules (Motterlini et al., 2003) which 
will greatly aid investigations in this area.
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Work in this lab utilises a astrocyte-neurone co-culture system to study astrocyte 
neurone interactions and inducing HO-1 in astrocytes, then culturing them with 
neurones may enable us to investigate if astrocytes can be protective via the HO 
pathway, and facilitate elucidation of the mechanisms by which protection may 
occur.
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